<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>c40966_10k.htm
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">


<center>
  <hr noshade>
  <hr noshade>
  <B><FONT face="serif">SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>
  <B><FONT face="serif">Washington, D.C. 20549</FONT></B><BR>
  <hr width="250" size="1" noshade>
  <B><FONT size=5 face="serif">FORM 10 &#150; K</FONT></B>
</center>
<TABLE width="70%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
  <TD colspan="2" align=left><hr size="1" noshade>    </TD>
  </TR>
<TR valign="bottom">
  <TD width=5% align=left>&nbsp;</TD>
	<TD width=95% align=left>
<B><FONT size=2 face="serif">(Mark One)</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>|X|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
	<TD align=left>
<B><FONT size=2 face="serif">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
	<TD align=left>
<B><FONT size=2 face="serif">SECURITIES EXCHANGE ACT OF 1934</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
  <TD align=center>&nbsp;</TD>
	<TD align=center>
<B><FONT size=5 face="serif">For the fiscal year ended December 31, 2005</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
  <TD align=left>|&nbsp;&nbsp;&nbsp;|</TD>
	<TD align=left>
<B><FONT size=2 face="serif">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
	<TD align=left>
<B><FONT size=2 face="serif">SECURITIES EXCHANGE ACT OF 1934</FONT></B>&nbsp;
	</TD>
</TR>
</TABLE>
<center>
  <BR>
  <B><FONT size=2 face="serif">For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to </FONT></B>
</center>
<P align="center"><B><FONT size=2 face="serif">Commission file number 1-3619</FONT></B></P>
<P align="center">
<B><FONT size=5 face="serif">PFIZER INC.</FONT></B><BR>
<FONT size=2 face="serif">(Exact name of registrant as specified in its charter)</FONT></P>
<TABLE width="70%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=50% align=center>
<B><FONT size=2 face="serif">Delaware</FONT></B>&nbsp;
	</TD>
	<TD align=center>
<B><FONT size=2 face="serif">13-5315170</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">(State or other jurisdiction of</FONT>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">(I.R.S. Employer</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">incorporation or organization)</FONT>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Identification Number)</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">235 East 42nd Street</FONT>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">10017-5755</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">New York, New York</FONT>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">(Zip Code)</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">(Address of principal executive offices)</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
</TABLE>
<center>
  <BR>
  <B><FONT size=2 face="serif">(212) 573-2323</FONT></B><BR>
  <U><FONT size=2 face="serif">(Registrant&#146;s telephone number, including
  area code)</FONT></U><BR>
  <B><FONT size=2 face="serif">Securities registered pursuant to Section 12(b) of the Act:</FONT></B><BR>
</center>
<hr noshade>
<hr noshade>
<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=50% align=center>
<B><FONT size=2 face="serif">Title of each class</FONT></B>&nbsp;
	</TD>
	<TD align=center>
<B><FONT size=2 face="serif">Name of each exchange</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=left>&nbsp;

	</TD>
	<TD align=center>
<B><FONT size=2 face="serif">on which registered</FONT></B>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD width=50% align=center>
<FONT size=2 face="serif">Common Stock, &#36;.05 par value</FONT>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">New York Stock Exchange</FONT>&nbsp;
	</TD>
</TR>
</TABLE>
<hr noshade>
<hr noshade>
<center>
  <B><FONT size=2 face="serif">Securities registered pursuant to Section 12(g) of the Act:</FONT></B>
</center>
<div align="center">
<B><FONT size=2 face="serif">None</FONT></B><p></P>
<hr width="200" size="1" noshade></div>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</FONT></P>
<P align="center">
<FONT size=2 face="serif">Yes |X|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No | &nbsp;&nbsp;&nbsp;|</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.</FONT></P>
<P align="center"> <FONT size=2 face="serif">Yes |&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
    |X&nbsp;|</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</FONT></P>
<P align="center"> <FONT size=2 face="serif">Yes |X|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No | &nbsp;&nbsp;&nbsp;|</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is
not contained herein, and will not be contained, to the best of registrant&#146;s
knowledge,  in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. |&nbsp;&nbsp;&nbsp;| </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &#147;accelerated filer and large accelerated
filer&#148; in Rule 12b-2 of the Exchange Act.</FONT></P>
<P align="center">
<FONT size=2 face="serif">Large accelerated filer&nbsp;&nbsp; |X| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated
filer&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;|</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </FONT></P>
<P align="center"> <FONT size=2 face="serif">Yes | &nbsp;&nbsp;&nbsp;| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No |X|</FONT></P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The
  aggregate market value of the voting stock held by non-affiliates of the registrant,
    computed by reference to the closing price as of the last business day of
    the registrant&#146;s most recently completed second fiscal quarter, July 1, 2005, was
  approximately &#36;162 billion. The registrant has no non-voting common stock.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The number of shares outstanding of each of the registrant&#146;s classes of common stock as of February 21, 2006 was 7,357,943,810 shares of common stock, all of one class.</FONT></P>
<P align="center">
<B><FONT size=2 face="serif">DOCUMENTS INCORPORATED BY REFERENCE</FONT></B></P>
<TABLE width="100%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=73% align=left>
<FONT size=2 face="serif">Portions of the 2005 Annual Report to Shareholders</FONT>&nbsp;
	</TD>
	<TD width=27% align=left>
<FONT size=2 face="serif">Parts I, II and IV</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Portions of the Proxy Statement for the 2006 Annual Meeting of Shareholders</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Parts I and III</FONT>&nbsp;
	</TD>
</TR>
</TABLE>


<hr noshade>
<hr noshade>

<P align="left" style="page-break-before:always"></P><PAGE>


<P align="center">
<B><FONT face="serif">TABLE OF CONTENTS</FONT></B></P>
<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD colspan=3 align=right>
<B><FONT size=2 face="serif">Page</FONT></B>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">PART I</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">1</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 1. BUSINESS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">1</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">General</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">1</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Pfizer Website</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">1</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Business Segments</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">2</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Human Health Segment</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">2</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Consumer Healthcare Segment</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">5</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Animal Health Segment</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">6</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Research and Product Development</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">6</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">International Operations</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">7</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Marketing</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">8</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Patents and Intellectual Property Rights</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">9</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Competition</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">10</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Raw Materials</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">12</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Government Regulation and Price Constraints</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">12</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Environmental Law Compliance</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">15</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Tax Matters</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">15</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">Employees</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">15</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 1A. RISK FACTORS AND CAUTIONARY FACTORS THAT MAY AFFECT</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">FUTURE RESULTS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">15</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 1B. UNRESOLVED STAFF COMMENTS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">19</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 2. PROPERTIES</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">19</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 3. LEGAL PROCEEDINGS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">19</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">19</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">EXECUTIVE OFFICERS OF THE COMPANY</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">20</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">PART II</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">20</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 5. MARKET FOR THE COMPANY&#146;S COMMON EQUITY, RELATED STOCKHOLDER</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">20</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 6. SELECTED FINANCIAL DATA</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">21</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 7. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">RESULTS OF OPERATIONS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">21</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">21</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">21</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">FINANCIAL DISCLOSURE</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">22</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 9A. CONTROLS AND PROCEDURES</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">22</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 9B. OTHER INFORMATION</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">22</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">PART III</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">22</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">22</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 11. EXECUTIVE COMPENSATION</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">23</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">AND RELATED STOCKHOLDER MATTERS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">23</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">23</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">23</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">PART IV</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">24</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<B><FONT size=2 face="serif">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</FONT></B>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">24</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">15(a)(1) Financial Statements</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">24</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">15(a)(2) Financial Statement Schedules</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">24</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
 &nbsp; &nbsp; &nbsp; &nbsp;<FONT size=2 face="serif">15(a)(3) Exhibits</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
<FONT size=2 face="serif">24</FONT>&nbsp;
	</TD>
</TR>
</TABLE><BR>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P align="center">
<B><FONT face="serif">PART I</FONT></B></P>
<P>
<B><FONT face="serif">ITEM 1. BUSINESS</FONT></B></P>
<P>
<B><FONT face="serif">General</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pfizer Inc. (which may be referred to as </FONT><I><FONT size=2 face="serif">Pfizer, the Company, we</FONT></I><FONT size=2 face="serif">, </FONT><I><FONT size=2 face="serif">us
</FONT></I><FONT size=2 face="serif">or </FONT><I><FONT size=2 face="serif">our</FONT></I><FONT size=2 face="serif">) is a research-based, global pharmaceutical company. We discover, develop, manufacture and market leading prescription medicines for
humans and animals as well as many of the world&#146;s best known consumer healthcare products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The Company was incorporated under the laws of the State of Delaware on June 2, 1942.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We acquired Warner-Lambert Company (Warner-Lambert) in June 2000. The acquisition was accounted for as a pooling of interests. In accordance with generally accepted accounting principles in the
U.S. (GAAP), we restated all consolidated financial statements of Pfizer for periods prior to the acquisition to include the results of operations and financial position of Warner-Lambert as if we had always been merged.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We acquired Pharmacia Corporation (Pharmacia) in April 2003. The acquisition was accounted for as a purchase. In accordance with GAAP, we did not restate our results of operations and financial
position to reflect the historical results of operations and financial position of Pharmacia.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We acquired Esperion Therapeutics, Inc. (&#147;Esperion&#148;) in February 2004. The acquisition was accounted for as a purchase. Esperion is a biopharmaceutical company focused on the
development of high density lipoprotein (HDL)-targeted (&#147;good cholesterol&#148;) therapies for the treatment of cardiovascular disease.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We acquired Idun Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis (cell death), in April 2005. The acquisition was
accounted for as a purchase. In September 2005, we acquired Vicuron Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel anti-infectives. The acquisition was also accounted for as a purchase.</FONT></P>
<P>
<B><FONT face="serif">Pfizer Website</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 are available on our website (www.pfizer.com) under the &#147;Who We Are - For Investors - SEC Filings by Pfizer&#148; captions as soon as reasonably practicable after we electronically file such material with, or
furnish it to, the Securities and Exchange Commission (SEC).</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Throughout this 2005 Form 10-K, we &#147;incorporate by reference&#148; certain information from parts of other documents filed with the SEC, including our Annual Report to Shareholders for
2005 and our Proxy Statement for the 2006 Annual Meeting of Shareholders (2006 Proxy Statement). The SEC allows us to disclose important information by referring to it in that manner. Please refer to such information. This year, our Annual Report to
Shareholders is in two parts: the 2005 Annual Review (2005 Annual Review); and the 2005 Financial Report (2005 Financial Report), which is contained in Appendix A to our 2006 Proxy Statement. Portions of our 2005 Financial Report are filed as
Exhibit 13 to this 2005 Form 10-K. On or about March 16, 2006, our 2005 Annual Review, our 2005 Financial Report and our 2006 Proxy Statement will be available on our website (www.pfizer.com); the 2005 Annual Review and 2005 Financial Report will be
set forth under the &#147;Who We Are - For Investors - Financial Reports&#148; captions, and the 2006 Proxy Statement will be set forth under the &#147;Who We Are - For Investors - SEC Filings by Pfizer&#148; captions.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Chief Executive Officer and Chief Financial Officer
certifications; Pfizer Policies on Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for our Directors; as well as
information concerning our Directors; e-mail communication with our Directors; Board Committees, including Committee charters; and transactions in Pfizer securities by Directors and officers, is available on our website</FONT></P>
<P align="center">
<FONT size=2 face="serif">1</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">(www.pfizer.com) under the &#147;Who We Are - For Investors - Corporate Governance&#148; captions. We will provide any of the foregoing information without charge upon written request to Margaret M. Foran, Senior Vice
President-Corporate Governance, Associate General Counsel and Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, NY 10017-5755. Information relating to shareholder services, including our Shareholder Investment Program, book-entry
share ownership and direct deposit of dividends, is available on our website (www.pfizer.com) under the &#147;Who We Are - For Investors - Shareholder Services&#148; captions.</FONT></P>
<P>
<B><FONT face="serif">Business Segments</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We operate in three business segments: Human Health, Consumer Healthcare and Animal Health.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We also operate several other businesses, including the manufacture of empty soft-gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. Due to the size of these
businesses, they are grouped into the &#147;Corporate/Other&#148; category of our segment information.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Comparative segment revenues and related financial information for 2005, 2004 and 2003 are presented in the table captioned <I>Segment </I>in Note 19 to our consolidated financial statements, <I>Segment, Geographic and Revenue Information, </I>in our 2005 Financial Report and the section headed </FONT><I><FONT size=2 face="serif">Revenues by Therapeutic Area </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report. The information from those sections of our 2005 Financial Report is incorporated by reference in this 2005 Form
10-K.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our businesses are heavily regulated in most of the countries where we operate. In the U.S., the principal authority regulating our operations is the Food and Drug Administration (FDA). The FDA
regulates the safety and efficacy of the products we offer and our research quality, manufacturing processes, product promotion, advertising and product labeling. Similar regulations exist in most other countries, and in many countries the
government also regulates our prices. See <I>Government Regulation and Price Constraints </I>below.</FONT></P>
<P>
<B><FONT face="serif">Human Health Segment</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Human Health business is the largest pharmaceutical business in the world. This segment includes treatments for cardiovascular and metabolic diseases, central nervous system disorders,
arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies. Our portfolio of medicines includes four of the world&#146;s 25 best-selling medicines, with six medicines that
lead their therapeutic areas.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In 2005, Human Health revenues declined 4%, to &#36;44.3 billion, primarily due to loss of U.S. exclusivity of certain key products (primarily </FONT><I><FONT size=2
face="serif">Neurontin</FONT></I><FONT size=2 face="serif">), uncertainty relating to selective COX-2 inhibitors and the suspension of sales of </FONT><I><FONT size=2 face="serif">Bextra</FONT></I><FONT size=2 face="serif">. 2005 results were also
impacted by increased competition and the overall market decline as branded prescriptions in the U.S. declined 5% in 2005 compared to 2004. Revenues from this segment contributed 86% of our total revenues in 2005, and 88% in each of 2004 and 2003.
We recorded product sales of more than &#36;1 billion for each of eight pharmaceutical products in 2005. Those eight products &#151; </FONT><I><FONT size=2 face="serif">Lipitor, Norvasc, Zoloft, Celebrex, Zithromax/Zmax, Viagra, Xalatan/Xalacom and
Zyrtec &#151; </FONT></I><FONT size=2 face="serif">represented 64 % of Human Health revenues in 2005. A table captioned </FONT><I><FONT size=2 face="serif">Revenues </FONT></I><FONT size=2 face="serif">- </FONT><I><FONT size=2 face="serif">Major
Human Health Products, </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report is incorporated by reference.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our principal pharmaceutical products and certain recently approved products are as follows:</FONT></P>
<P>
<I><FONT size=2 face="serif">Cardiovascular and Metabolic Diseases</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Lipitor, </FONT></I><FONT size=2 face="serif">for the treatment of elevated</FONT> <FONT size=2 face="serif">cholesterol levels in the blood, is the most</FONT> <FONT size=2 face="serif">widely used treatment for
lowering cholesterol</FONT> <FONT size=2 face="serif">and the best-selling pharmaceutical product of</FONT> <FONT size=2 face="serif">any kind in the world. In September 2005, the</FONT> <FONT size=2 face="serif">FDA approved the use of
</FONT><I><FONT size=2 face="serif">Lipitor </FONT></I><FONT size=2 face="serif">to reduce the</FONT> <FONT size=2 face="serif">risk of stroke and myocardial infarction in</FONT> <FONT size=2 face="serif">patients with type 2 diabetes and multiple
risk</FONT> <FONT size=2 face="serif">factors for coronary heart disease. In addition,</FONT> <FONT size=2 face="serif">the FDA expanded the </FONT><I><FONT size=2 face="serif">Lipitor </FONT></I><FONT size=2 face="serif">label to include</FONT>
<FONT size=2 face="serif">data on the reduction in the incidence of stroke</FONT> <FONT size=2 face="serif">in patients with multiple risk factors.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Norvasc </FONT></I><FONT size=2 face="serif">is the world&#146;s most-prescribed</FONT> <FONT size=2 face="serif">branded medicine for treating hypertension.</FONT></LI>
</UL>
<P align="center">
<FONT size=2 face="serif">2</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<UL>
<I><FONT size=2 face="serif">Norvasc </FONT></I><FONT size=2 face="serif">experienced patent expirations in</FONT> <FONT size=2 face="serif">many European Union (E.U.) countries.</FONT> <I><FONT size=2 face="serif">Norvasc </FONT></I><FONT size=2
face="serif">maintains exclusivity in many major</FONT> <FONT size=2 face="serif">markets globally, including the U.S., Japan,</FONT> <FONT size=2 face="serif">Canada and Australia.</FONT>
<br>
<br>
<LI>
<I><FONT size=2 face="serif">Caduet, </FONT></I><FONT size=2 face="serif">launched
in the U.S. in 2004, is a</FONT> <FONT size=2 face="serif">single pill combining </FONT><I><FONT size=2 face="serif">Lipitor </FONT></I><FONT size=2 face="serif">and
</FONT><I><FONT size=2 face="serif">Norvasc </FONT></I><FONT size=2 face="serif">for</FONT> <FONT size=2 face="serif">prevention
of cardiovascular events. </FONT><I><FONT size=2 face="serif">Caduet</FONT></I> <FONT size=2 face="serif">has
been approved in several European countries for the prevention of cardiovascular
events. <br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Accupril/Accuretic </FONT></I><FONT size=2 face="serif">is
an angiotensin</FONT> <FONT size=2 face="serif">converting enzyme (ACE) inhibitor
for the</FONT> <FONT size=2 face="serif">treatment of hypertension and
congestive heart</FONT> <FONT size=2 face="serif">failure. </FONT><I><FONT size=2 face="serif">Accupril </FONT></I><FONT size=2 face="serif">began
to face generic</FONT> <FONT size=2 face="serif">competition in the latter part
of 2004.</FONT> <FONT size=2 face="serif">Subsequently, we launched our own generic</FONT> <FONT size=2 face="serif">version
of </FONT><I><FONT size=2 face="serif">Accupril </FONT></I><FONT size=2 face="serif">in
the U.S. through our</FONT> <FONT size=2
face="serif">Greenstone Ltd. (&#147;Greenstone&#148;) generic</FONT> <FONT size=2 face="serif">pharmaceutical
subsidiary.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Cardura </FONT></I><FONT size=2 face="serif">is for the treatment of hypertension</FONT> <FONT size=2 face="serif">and benign prostatic hyperplasia (enlarged</FONT> <FONT size=2 face="serif">prostate gland). Currently,
there are multiple</FONT> <FONT size=2 face="serif">generic versions of </FONT><I><FONT size=2 face="serif">Cardura </FONT></I><FONT size=2 face="serif">on the U.S.</FONT> <FONT size=2 face="serif">market. We expect to launch </FONT><I><FONT size=2
face="serif">Cardura XL</FONT></I><FONT size=2 face="serif">, an</FONT> <FONT size=2 face="serif">extended release version which has been</FONT> <FONT size=2 face="serif">approved by the FDA, in May 2006.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Inspra, </FONT></I><FONT size=2 face="serif">launched in the U.S. in 2004</FONT><I><FONT size=2 face="serif">, </FONT></I><FONT size=2 face="serif">is for</FONT> <FONT size=2 face="serif">the treatment of hypertension
and congestive</FONT> <FONT size=2 face="serif">heart failure in patients who have had a heart</FONT> <FONT size=2 face="serif">attack. It also was launched in several E.U.</FONT> <FONT size=2 face="serif">member countries in 2004 for the treatment
of</FONT> <FONT size=2 face="serif">congestive heart failure.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Revatio </FONT></I><FONT size=2 face="serif">was approved in the U.S. in June 2005</FONT> <FONT size=2 face="serif">and in the E.U. in November 2005 for the</FONT> <FONT size=2 face="serif">treatment of pulmonary
arterial hypertension,</FONT> <FONT size=2 face="serif">a rare, life-shortening vascular condition.</FONT></LI>
</UL>
<P>
<I><FONT size=2 face="serif">Central Nervous System Disorders</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Zoloft </FONT></I><FONT size=2 face="serif">is the
most-prescribed antidepressant in</FONT> <FONT size=2 face="serif">the U.S. It
is indicated for the treatment of</FONT> <FONT size=2 face="serif">major depressive
 disorder, panic disorder,</FONT> <FONT size=2 face="serif">obsessive-compulsive
 disorder in adults and</FONT> <FONT size=2 face="serif">children, post-traumatic
 stress disorder</FONT> <FONT size=2 face="serif">(PTSD), premenstrual dysphoric
  disorder</FONT> <FONT size=2 face="serif">(PMDD) and social anxiety disorder
  (SAD).</FONT> <I><FONT size=2 face="serif">Zoloft </FONT></I><FONT size=2 face="serif">is
  approved for acute and long-term use</FONT> <FONT size=2 face="serif">in all
  of these indications, with the exception</FONT> <FONT size=2 face="serif">of
  PMDD, and is the  only approved agent for</FONT> <FONT size=2 face="serif">the
  long-term treatment of PTSD and SAD, an important differentiating feature as these</FONT> <FONT size=2 face="serif">disorders tend to be chronic. For information</FONT> <FONT size=2 face="serif">concerning a labeling change implemented in</FONT> <FONT size=2
face="serif">the U.S. in February 2005, see the discussion</FONT> <FONT size=2 face="serif">under the headings </FONT><I><FONT size=2 face="serif">Human Health-Selected</FONT></I> <I><FONT size=2 face="serif">Product Descriptions, Zoloft
  </FONT></I><FONT size=2 face="serif">in the Financial</FONT> <FONT size=2 face="serif">Review section of our 2005 Financial Report,</FONT> <FONT size=2 face="serif">which discussion is incorporated by reference.</FONT></LI>
</UL>
<UL>
  <LI>
<I><FONT size=2 face="serif">Neurontin, </FONT></I><FONT size=2 face="serif">for
use in adjunctive therapy for</FONT> <FONT size=2 face="serif">epilepsy, is also
approved in many countries</FONT> <FONT size=2 face="serif">for the treatment
of a  range of neuropathic</FONT> <FONT size=2 face="serif">pain conditions. </FONT><I><FONT size=2 face="serif">Neurontin </FONT></I><FONT size=2 face="serif">has
also been</FONT> <FONT size=2 face="serif">approved for the management of
post-herpetic</FONT> <FONT size=2 face="serif">neuralgia, a painful condition
that affects</FONT> <FONT size=2 face="serif">many people in the aftermath of
the viral</FONT> <FONT size=2 face="serif">infection commonly known as shingles.</FONT> <I><FONT size=2 face="serif">Neurontin </FONT></I><FONT size=2 face="serif">began
to face generic competition</FONT> <FONT size=2 face="serif">in the U.S. in the
latter half of 2004.</FONT> <FONT size=2 face="serif">Subsequently, we launched
our own generic</FONT> <FONT size=2 face="serif">version
of </FONT><I><FONT size=2 face="serif">Neurontin </FONT></I><FONT size=2 face="serif">in
the U.S. through our</FONT> <FONT size=2
face="serif">Greenstone subsidiary.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Geodon</FONT></I><FONT size=2 face="serif">, marketed in certain countries as</FONT> <I><FONT size=2 face="serif">Zeldox, </FONT></I><FONT size=2 face="serif">is a treatment for the symptoms of</FONT> <FONT size=2
face="serif">schizophrenia and bipolar disorder, including</FONT> <FONT size=2 face="serif">manic and mixed episodes. Available in both</FONT> <FONT size=2 face="serif">an oral capsule and rapid-acting intramuscular</FONT> <FONT size=2
face="serif">formulation, </FONT><I><FONT size=2 face="serif">Geodon </FONT></I><FONT size=2 face="serif">is now the second-</FONT> <FONT size=2 face="serif">fastest-growing atypical anti-psychotic</FONT> <FONT size=2 face="serif">medication in the
U.S.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Aricept</FONT></I><FONT size=2 face="serif">, discovered and developed by Eisai</FONT> <FONT size=2 face="serif">Co., Ltd., is the world&#146;s leading medicine to</FONT> <FONT size=2 face="serif">treat symptoms of
Alzheimer&#146;s disease. We co-</FONT> <FONT size=2 face="serif">promote </FONT><I><FONT size=2 face="serif">Aricept </FONT></I><FONT size=2 face="serif">with Eisai in the U.S. and</FONT> <FONT size=2 face="serif">several other countries and have
an exclusive</FONT> <FONT size=2 face="serif">license to sell this medicine in certain other</FONT> <FONT size=2 face="serif">countries.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Xanax </FONT></I><FONT size=2 face="serif">is for
the treatment of generalized</FONT> <FONT size=2 face="serif">anxiety disorder
and panic disorder. </FONT><I><FONT size=2 face="serif">Xanax</FONT></I> <I><FONT size=2
face="serif">XR</FONT></I><FONT size=2 face="serif">, an extended-release formulation
of the</FONT> <FONT size=2 face="serif">drug, is a rapid-acting, once-a-day medication</FONT> <FONT size=2 face="serif">approved
for treating panic disorder.  The</FONT> <I><FONT size=2 face="serif">Xanax XR </FONT></I><FONT size=2 face="serif">patent
has expired in the U.S. and</FONT> <FONT size=2 face="serif">we anticipate generic
competition in 2006.</FONT> <FONT size=2 face="serif">Pfizer&#146;s Greenstone
subsidiary will also launch</FONT> <FONT size=2 face="serif">a generic version.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Relpax </FONT></I><FONT size=2 face="serif">is an oral treatment for acute migraine</FONT> <FONT size=2 face="serif">headaches. It has been launched in the U.S.,</FONT> <FONT size=2 face="serif">Canada, Japan and
throughout Europe.</FONT></LI>
</UL>
<P align="center">
<FONT size=2 face="serif">3</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<UL>
<LI>
<I><FONT size=2 face="serif">Rebif, </FONT></I><FONT size=2 face="serif">discovered and developed by Serono</FONT> <FONT size=2 face="serif">S.A., is used for the treatment of relapsing</FONT> <FONT size=2 face="serif">forms of multiple sclerosis.
We co-promote</FONT> <I><FONT size=2 face="serif">Rebif </FONT></I><FONT size=2 face="serif">with Serono in the U.S.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Lyrica </FONT></I><FONT size=2 face="serif">was approved by the FDA in June 2005</FONT> <FONT size=2 face="serif">for adjunctive therapy for adults with partial</FONT> <FONT size=2 face="serif">onset seizures. This
latest indication builds on</FONT> <FONT size=2 face="serif">the December 2004 FDA approval of </FONT><I><FONT size=2 face="serif">Lyrica</FONT></I> <FONT size=2 face="serif">for two of the most common forms of</FONT> <FONT size=2
face="serif">neuropathic pain &#151; diabetic peripheral</FONT> <FONT size=2 face="serif">neuropathy, a chronic neurologic condition</FONT> <FONT size=2 face="serif">affecting nearly three million Americans, and</FONT> <FONT size=2
face="serif">post-herpetic neuralgia. </FONT><I><FONT size=2 face="serif">Lyrica </FONT></I><FONT size=2 face="serif">was launched</FONT> <FONT size=2 face="serif">in the U.S., Canada and Italy in September</FONT> <FONT size=2 face="serif">2005 and
is now approved in more than 50</FONT> <FONT size=2 face="serif">countries and is currently available in more</FONT> <FONT size=2 face="serif">than 30 markets.</FONT></LI>
</UL>
<P>
<I><FONT size=2 face="serif">Arthritis and Pain</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Celebrex </FONT></I><FONT size=2 face="serif">is
for the treatment of osteoarthritis,</FONT> <FONT size=2 face="serif">adult rheumatoid
arthritis, acute pain,</FONT> <FONT size=2 face="serif">menstrual pain and familial
 adenomatous</FONT> <FONT size=2 face="serif">polyposis. It also was approved
 by the FDA in</FONT> <FONT size=2 face="serif">July 2005 for the treatment of
 ankylosing</FONT> <FONT size=2 face="serif">spondylitis, a form of spinal arthritis.
</FONT><I><FONT size=2 face="serif">Celebrex</FONT></I> <FONT size=2 face="serif">has
the broadest range of approved indications</FONT> <FONT size=2 face="serif">of
any selective COX-2 inhibitor. See the</FONT> <FONT size=2 face="serif">discussion
 of labeling changes relating to</FONT> <I><FONT size=2 face="serif">Celebrex </FONT></I><FONT size=2 face="serif">and
 the suspension of </FONT><I><FONT size=2 face="serif">Bextra,</FONT></I> <FONT size=2 face="serif">another
 arthritis medicine,  under the headings</FONT> <I><FONT size=2 face="serif">Human
 Health-Selected Product Descriptions,</FONT></I> <I><FONT size=2 face="serif">Celebrex
 and Bextra, </FONT></I><FONT size=2 face="serif">in the Financial Review</FONT> <FONT size=2 face="serif">section
 of our 2005  Financial Report, which is</FONT> <FONT size=2 face="serif">incorporated
 by reference.</FONT></LI>
</UL>
<P>
<I><FONT size=2 face="serif">Infectious and Respiratory Diseases</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Zithromax </FONT></I><FONT size=2 face="serif">is for the treatment of bacterial</FONT> <FONT size=2 face="serif">infections. </FONT><I><FONT size=2 face="serif">Zithromax </FONT></I><FONT size=2 face="serif">is licensed
to us</FONT> <FONT size=2 face="serif">exclusively by Pliva, a Croatian</FONT> <FONT size=2 face="serif">pharmaceutical company. </FONT><I><FONT size=2 face="serif">Zithromax </FONT></I><FONT size=2 face="serif">lost basic</FONT> <FONT size=2
face="serif">patent protection in the U.S. in November</FONT> <FONT size=2 face="serif">2005. During the fourth quarter of 2005, four</FONT> <FONT size=2 face="serif">generic versions of the oral solid dosage form</FONT> <FONT size=2 face="serif">of
azithromycin were launched, including one</FONT> <FONT size=2 face="serif">authorized generic by Pfizer&#146;s Greenstone</FONT> <FONT size=2 face="serif">subsidiary.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Zmax</FONT></I><B><FONT size=2 face="serif">, </FONT></B><FONT size=2 face="serif">a single-dose, sustained-release form of</FONT> <FONT size=2 face="serif">azithromycin, was made available to patients</FONT> <FONT
size=2 face="serif">in the U.S. beginning in August 2005. </FONT><I><FONT size=2 face="serif">Zmax</FONT></I><FONT size=2 face="serif">,</FONT> <FONT size=2 face="serif">which is a novel and patent-protected formulation, delivers a complete course of</FONT> <FONT size=2 face="serif">therapy in a single dose and helps minimize</FONT> <FONT size=2 face="serif">non-compliance compared to multi-dose</FONT> <FONT size=2
face="serif">regimes.</FONT></LI>
</UL>
<UL><LI>
<I><FONT size=2 face="serif">Diflucan </FONT></I><FONT size=2 face="serif">is a systemic antifungal. It is used to</FONT> <FONT size=2 face="serif">treat various fungal infections, including</FONT> <FONT size=2 face="serif">vaginal infections and
certain infections that</FONT> <FONT size=2 face="serif">afflict HIV/AIDS and cancer patients with</FONT> <FONT size=2 face="serif">weakened immune systems. </FONT><I><FONT size=2 face="serif">Diflucan </FONT></I><FONT size=2
face="serif">lost</FONT> <FONT size=2 face="serif">patent protection in Japan and much of Europe</FONT> <FONT size=2 face="serif">in 2003, and lost marketing exclusivity in the</FONT> <FONT size=2 face="serif">U.S. in 2004. Subsequently, we launched
our</FONT> <FONT size=2 face="serif">own generic version of </FONT><I><FONT size=2 face="serif">Diflucan </FONT></I><FONT size=2 face="serif">in the U.S.</FONT> <FONT size=2 face="serif">through our Greenstone subsidiary.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Vfend </FONT></I><FONT size=2 face="serif">is a treatment that can be administered</FONT> <FONT size=2 face="serif">orally or intravenously for certain serious and</FONT> <FONT size=2 face="serif">potentially fatal
fungal infections, for the</FONT> <FONT size=2 face="serif">treatment of esophageal candidiasis and for</FONT> <FONT size=2 face="serif">the treatment of certain blood stream</FONT> <FONT size=2 face="serif">infections in non-neutropenic patients
(those</FONT> <FONT size=2 face="serif">without low white blood cell counts). It is also</FONT> <FONT size=2 face="serif">available in an oral-suspension formulation</FONT> <FONT size=2 face="serif">suitable for patients unable to swallow the</FONT>
<FONT size=2 face="serif">tablet form.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Zyvox </FONT></I><FONT size=2 face="serif">is for the treatment of bacterial</FONT> <FONT size=2 face="serif">infections, which increasingly are caused by</FONT> <FONT size=2 face="serif">drug-resistant bacteria, and the
treatment of</FONT> <FONT size=2 face="serif">diabetic foot infections. </FONT><I><FONT size=2 face="serif">Zyvox </FONT></I><FONT size=2 face="serif">is available in</FONT> <FONT size=2 face="serif">intravenous, tablet and oral-suspension</FONT>
<FONT size=2 face="serif">formulations.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Spiriva </FONT></I><FONT size=2 face="serif">is
for the treatment of chronic</FONT> <FONT size=2 face="serif">obstructive pulmonary
disease (COPD), a</FONT> <FONT size=2 face="serif">chronic respiratory disorder
that  includes</FONT> <FONT size=2 face="serif">bronchitis and emphysema. We
co-promote</FONT> <I><FONT size=2 face="serif">Spiriva </FONT></I><FONT size=2 face="serif">with
Boehringer Ingelheim, which</FONT> <FONT size=2 face="serif">discovered and
developed the medicine.</FONT> <I><FONT size=2 face="serif">Spiriva HandiHaler </FONT></I><FONT size=2 face="serif">is
an inhaled treatment for</FONT> <FONT size=2 face="serif">the long-term, once-daily
maintenance</FONT> <FONT size=2 face="serif">treatment of bronchospasm
associated with</FONT> <FONT size=2 face="serif">COPD.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Exubera </FONT></I><FONT size=2 face="serif">(inhaled
human insulin) was</FONT> <FONT size=2 face="serif">approved by the FDA and the
European</FONT> <FONT size=2 face="serif">Commission in January 2006 for the
 treatment</FONT> <FONT size=2 face="serif">of adults with type 1 and type 2
 diabetes.</FONT> <I><FONT size=2 face="serif">Exubera </FONT></I><FONT size=2 face="serif">is
 a product of a collaboration</FONT> <FONT size=2 face="serif">between Pfizer
 and Nektar Therapeutics. We</FONT> <FONT size=2 face="serif">expect to launch </FONT><I><FONT
size=2 face="serif">Exubera </FONT></I><FONT size=2 face="serif">in the U.S.
 and</FONT> <FONT size=2 face="serif">selected E.U. markets by mid-year. See
 the</FONT> <FONT size=2 face="serif">discussion of our pending acquisition of</FONT></LI>
</UL>
<P align="center">
<FONT size=2 face="serif">4</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<blockquote>
  <p>
    <FONT size=2 face="serif">worldwide rights related to </FONT><I><FONT size=2 face="serif">Exubera </FONT></I><FONT size=2 face="serif">under the heading </FONT><I><FONT size=2 face="serif">Acquisitions and Dispositions&#151;Other Acquisitions
  </FONT></I><FONT size=2 face="serif">in the Financial Review Section of our 2005 Financial Report, which is incorporated by reference.</FONT></p>
</blockquote>
<P>
<I><FONT size=2 face="serif">Urology</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Viagra </FONT></I><FONT size=2 face="serif">is the
leading treatment for erectile</FONT> <FONT size=2 face="serif">dysfunction (ED),
and one of the world&#146;s most</FONT> <FONT size=2 face="serif">recognized
 pharmaceutical brands. For further</FONT> <FONT size=2 face="serif">information
 on </FONT><I><FONT size=2 face="serif">Viagra </FONT></I><FONT size=2 face="serif">and
 the overall ED</FONT> <FONT size=2 face="serif">market, see the discussion under
  the headings</FONT> <I><FONT size=2 face="serif">Human Health-Selected Product
  Descriptions</FONT></I><FONT size=2 face="serif">,</FONT> <I><FONT size=2 face="serif">Viagra </FONT></I><FONT size=2 face="serif">in
  the Financial Review section of our</FONT> <FONT size=2
face="serif">2005 Financial Report, which is incorporated</FONT> <FONT size=2 face="serif">by
  reference.<br>
  <br>
  </FONT></LI>
<LI>
<I><FONT size=2 face="serif">Detrol </FONT></I><FONT size=2 face="serif">is the world&#146;s leading product for the</FONT> <FONT size=2 face="serif">treatment of overactive bladder. </FONT><I><FONT size=2 face="serif">Detrol LA </FONT></I><FONT
size=2 face="serif">is</FONT> <FONT size=2 face="serif">an extended-release formulation of this</FONT> <FONT size=2 face="serif">medicine, taken once a day.</FONT></LI>
</UL>
<P>
<I><FONT size=2 face="serif">Oncology</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Camptosar</FONT></I><FONT size=2 face="serif">, which is marketed under the name</FONT> <I><FONT size=2 face="serif">Campto </FONT></I><FONT size=2 face="serif">in many countries outside the U.S., is</FONT> <FONT size=2
face="serif">one of the leading treatments for colorectal</FONT> <FONT size=2 face="serif">cancer. In addition to our U.S. rights, in</FONT> <FONT size=2 face="serif">October 2004, we acquired marketing rights to</FONT> <I><FONT size=2
face="serif">Campto/Camptosar </FONT></I><FONT size=2 face="serif">in Europe and Asia (except</FONT> <FONT size=2 face="serif">Japan).<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Ellence </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Aromasin </FONT></I><FONT size=2 face="serif">are for the treatment of</FONT> <FONT size=2 face="serif">breast cancer. In 2005,
</FONT><I><FONT size=2 face="serif">Aromasin </FONT></I><FONT size=2 face="serif">was approved</FONT> <FONT size=2 face="serif">in the U.S. and E.U. to treat early breast cancer</FONT> <FONT size=2 face="serif">in post-menopausal women.<br>
<br>
</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Sutent</FONT></I><FONT size=2 face="serif">, a new targeted anti-cancer treatment</FONT> <FONT size=2 face="serif">for patients with gastrointestinal stromal</FONT> <FONT size=2 face="serif">tumors, a rare stomach
cancer, and advanced</FONT> <FONT size=2 face="serif">kidney cancer, was approved by the FDA for</FONT> <FONT size=2 face="serif">both indications in January 2006. Applications</FONT> <FONT size=2 face="serif">for these indications have also been
filed in</FONT> <FONT size=2 face="serif">Canada and the E.U. </FONT><I><FONT size=2 face="serif">Sutent </FONT></I><FONT size=2 face="serif">was available to</FONT> <FONT size=2 face="serif">patients in the U.S. within seven days of its</FONT>
<FONT size=2 face="serif">approval.</FONT></LI>
</UL>
<P>
<I><FONT size=2 face="serif">Ophthalmology</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Xalatan/Xalacom </FONT></I><FONT size=2 face="serif">is the most-prescribed</FONT> <FONT size=2 face="serif">branded glaucoma medicine in the world. It is</FONT> <FONT size=2 face="serif">used to treat open-angle
glaucoma and ocular</FONT> <FONT size=2 face="serif">hypertension. <I>Xalacom, </I>which consists of <I>Xalatan </I>in combination with a beta blocker, is</FONT> <FONT size=2 face="serif">available primarily in European markets.</FONT></LI>
</UL>
<UL>
  <LI>
<I><FONT size=2 face="serif">Macugen </FONT></I><FONT size=2 face="serif">is
a treatment for neovascular (wet)</FONT> <FONT size=2 face="serif">age-related
macular degeneration (AMD).</FONT> <I><FONT size=2 face="serif">Macugen</FONT></I><FONT size=2 face="serif">,
which is jointly marketed by Pfizer</FONT> <FONT size=2 face="serif">and OSI
Pharmaceuticals in the U.S., has</FONT> <FONT size=2 face="serif">become the
most frequently used  treatment</FONT> <FONT size=2 face="serif">regimen for
wet AMD in the U.S. and received</FONT> <FONT size=2 face="serif">marketing authorization
in the E.U. in January</FONT> <FONT size=2 face="serif">2006. It was launched
in the U.S. in  January</FONT> <FONT size=2 face="serif">2005 and in Canada in
September 2005.</FONT></LI>
</UL>
<P align="left">
<I><FONT size=2 face="serif">Endocrine Disorders</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Genotropin </FONT></I><FONT size=2 face="serif">is the world&#146;s leading human</FONT> <FONT size=2 face="serif">recombinant growth hormone. It is used for</FONT> <FONT size=2 face="serif">the treatment of various
growth disorders in</FONT> <FONT size=2 face="serif">children and adults. Novo Nordisk has granted</FONT> <FONT size=2 face="serif">us a non-exclusive license to sell </FONT><I><FONT size=2 face="serif">Genotropin</FONT></I> <FONT size=2
face="serif">in the U.S.</FONT></LI>
</UL>
<P align="left">
<I><FONT size=2 face="serif">Other</FONT></I></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">is for
the treatment of year-round</FONT> <FONT size=2 face="serif">indoor and seasonal
outdoor allergies and</FONT> <FONT size=2 face="serif">hives in adults and children.
</FONT><I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">is
the</FONT> <FONT size=2 face="serif">most-prescribed antihistamine in the U.S.</FONT> <I><FONT size=2 face="serif">Zyrtec-D
12 Hour </FONT></I><FONT size=2 face="serif">treats both year-round</FONT> <FONT size=2 face="serif">indoor
and outdoor allergies as well as nasal</FONT> <FONT size=2 face="serif">congestion. </FONT><I><FONT
size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">is licensed to
us by the</FONT> <FONT size=2 face="serif">Belgian company UCB S.A. We co-promote</FONT> <I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">as
a  prescription medicine in the U.S.</FONT> <FONT size=2 face="serif">with a
subsidiary of UCB S.A. and we have a</FONT> <FONT size=2 face="serif">license
to sell </FONT><I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">under
 various trade</FONT> <FONT size=2 face="serif">names as an OTC medicine in Canada,</FONT> <FONT size=2 face="serif">Europe,
 Mexico and Australia.</FONT></LI>
</UL>
<P>
<B><FONT face="serif">Consumer Healthcare Segment</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Consumer Healthcare business is one of the largest in the world. We market many of the world&#146;s best-known OTC, or self-medications, for oral care, upper respiratory health, tobacco
dependence, gastrointestinal health, skin care, eye care and hair growth.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In 2005, Consumer Healthcare revenues increased 10%, to &#36;3.9 billion, due to the strong performance of Listerine mouthwash, which has benefited from recent product extensions and broader
sales of the product outside the U.S.; growth from upper-respiratory products, </FONT><I><FONT size=2 face="serif">Zantac </FONT></I><FONT size=2 face="serif">and tobacco dependence products; inclusion of</FONT></P>
<P align="center">
<FONT size=2 face="serif">5</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">Purell sales, following the acquisition of the Purell brand in November 2004; and the favorable impact of foreign exchange. Revenues from this segment contributed 7.6% of our total revenues in 2005, 6.7% of our total
revenues in 2004 and 6.6% of our total revenues in 2003.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Consumer Healthcare&#146;s principal products include:</FONT></P>
<UL>
<LI>
<I><FONT size=2 face="serif">Listerine </FONT></I><FONT size=2 face="serif">mouthwash</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Listerine PocketPaks </FONT></I><FONT size=2 face="serif">oral care strips</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Nicorette </FONT></I><FONT size=2 face="serif">for tobacco dependence</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Benadryl </FONT></I><FONT size=2 face="serif">antihistamine for allergies</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Sudafed </FONT></I><FONT size=2 face="serif">for sinus congestion</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Rogaine </FONT></I><FONT size=2 face="serif">for hair growth</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Zantac </FONT></I><FONT size=2 face="serif">for prevention and relief of heartburn</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Rolaids </FONT></I><FONT size=2 face="serif">antacid tablets</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Neosporin </FONT></I><FONT size=2 face="serif">antibiotic ointment</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Visine </FONT></I><FONT size=2 face="serif">eye drops</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Lubriderm </FONT></I><FONT size=2 face="serif">moisturizing lotions</FONT></LI>
<LI>
<I><FONT size=2 face="serif">Purell </FONT></I><FONT size=2 face="serif">instant hand sanitizer</FONT></LI>
</UL>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Consumer Healthcare can extend the life of some of our prescription medications by converting them to OTC products, or &#147;self-medications&#148;. For example, </FONT><I><FONT size=2
face="serif">Nicorette, Benadryl, Sudafed </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Zantac </FONT></I><FONT size=2 face="serif">were all previously prescription products. As market conditions permit, and when we
have necessary approval from drug regulatory authorities, we plan to pursue similar launches for other products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">On February 7, 2006, we announced that we will be exploring strategic alternatives for our Consumer Healthcare business, including spinning off or selling the business. We expect to make a
decision in the third quarter of 2006.</FONT></P>
<P>
<B><FONT face="serif">Animal Health Segment</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Animal Health business is one of the largest in the world. We discover, develop and sell products for the prevention and treatment of diseases in livestock and companion animals. In 2005,
Animal Health revenues increased 13%, to &#36; 2.2 billion, due to strong performances by <I>Excede </I>(a long acting anti-infective) in the U.S., <I>Draxxin </I>(for treatment of respiratory disease in cattle and swine) in the U.S. and Europe, the launch of <I>Spectramast </I>in the
U.S., double digit growth in sales of <I>Revolution </I>(a parasiticide for dogs and cats) and <I>Clavamox </I>(an
antibiotic for dogs and cats) for companion animals, the launch of Simplicef (small animal anti-infective) in the U.S. in the fourth quarter of 2004, and the favorable impact of foreign exchange. Revenues from this segment contributed 4.3% of our revenue in 2005, 3.7% of our total revenues
in 2004 and 3.6% of total revenues in 2003.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Among the products we market are parasiticides, anti-inflammatories, vaccines, antibiotics and related medicines, including the products discussed below.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Parasiticides constitute the largest segment of the animal health market for companion animals, consisting mainly of medicines for the control of parasites such as fleas and heartworm. Our
product, </FONT><I><FONT size=2 face="serif">Revolution</FONT></I><FONT size=2 face="serif">, is our largest-selling parasiticide for companion animals.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Spectramast</FONT></I><FONT size=2 face="serif">, an antibiotic formulated to treat clinical mastitis, was launched in the U.S. in May 2005.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Rimadyl </FONT></I><FONT size=2 face="serif">relieves pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery. </FONT><I><FONT size=2
face="serif">Rimadyl </FONT></I><FONT size=2 face="serif">is the only arthritis pain medication prescribed by veterinarians available in chewable tablets, regular caplets and in an injectable formulation.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Clavamox/Synulox </FONT></I><FONT size=2 face="serif">is an antibiotic for skin and soft tissue infections in dogs and cats.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our vaccine portfolio for livestock is extensive and includes </FONT><I><FONT size=2 face="serif">RespiSureOne/StellamuneOne, </FONT></I><FONT size=2 face="serif">a single-dose vaccine used to
prevent pneumonia in swine, and </FONT><I><FONT size=2 face="serif">Bovi-Shield Gold, </FONT></I><FONT size=2 face="serif">a cattle vaccine for reproductive and respiratory protection.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Dectomax </FONT></I><FONT size=2 face="serif">injectable and pour-on formulations remove and control internal and external parasites in beef cattle.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Naxcel/Excenel RTU </FONT></I><FONT size=2 face="serif">is an antibiotic used to treat respiratory and internal infections in cattle and swine.</FONT></P>
<P>
<B><FONT face="serif">Research and Product Development</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Innovation by our research and development operations is very important to the Company&#146;s success. Our goal is to discover, develop and bring to market innovative products that address
major unmet medical needs. This goal has been supported by our substantial research and development investments. We spent &#36;7.4 billion in 2005, &#36;7.7 billion in 2004 and &#36;7.5 billion in 2003</FONT></P>
<P align="center">
<FONT size=2 face="serif">6</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">on research and development in support of Pfizer&#146;s human, animal and consumer healthcare businesses.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We conduct research internally and also through contracts with third parties, through collaborations with universities and biotechnology companies and in cooperation with other pharmaceutical
firms. We also seek out innovative technologies developed by third parties to incorporate into our discovery or development processes or projects, as well as our product lines, through acquisition, licensing or other arrangements.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Drug discovery and development is time consuming, expensive and unpredictable. On average, only one out of many thousands of chemical compounds discovered by researchers proves to be both
medically effective and safe enough to become an approved medicine. The process from early discovery to development to regulatory approval can take more than ten years. Drug candidates can fail at any stage of the process. Candidates may not receive
regulatory approval even after many years of research.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We believe that our investments in research have been rewarded by the number of pharmaceutical compounds we have in all stages of development. We currently are working on 235 projects in
development, including 152 new molecular entities and 83 product-line extensions. In addition, we have more than 400 projects in discovery research. In recent years, our discovery scientists have delivered dozens of new chemical compounds to early
development. While these new candidates may or may not eventually receive regulatory approval, new drug candidates entering development are the foundation for future products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In addition to discovering
and developing new products, our research operations add value to our existing
products by improving their effectiveness and by discovering new uses for them.
In  2005, for example, we received approval for a new indication for our COX-2
inhibitor <I>Celebrex </I>for the treatment of ankylosing spondylitis, a form
of arthritis that affects the  spine. We also received approval for the use of <I>Lipitor </I>to
reduce the risk of stroke and heart attack in people with type 2 diabetes and
multiple risk factors for coronary heart disease.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information concerning several of our drug candidates in development as well as supplemental filings for existing products is set forth under the heading </FONT><I><FONT size=2
face="serif">Product Developments </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report. That information is incorporated by reference.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our competitors also devote substantial funds and resources to research and development. In addition, the consolidation that has occurred in our industry has created companies with substantial
research and development resources. We also compete against numerous small biotechnology companies in developing potential drug candidates. The extent to which our competitors are successful in their research could result in erosion of the sales of
our products and unanticipated product obsolescence.</FONT></P>
<P>
<B><FONT face="serif">International Operations</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We have significant operations outside the United States. They are managed through the same business segments as our U.S. operations - Human Health, Consumer Healthcare and Animal
Health.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Revenues from operations outside the U.S. of &#36;24.6 billion accounted for 48% of our total revenues in 2005. Revenues exceeded &#36;500 million in each of 12 countries outside the U.S. in
2005. The U.S. was the only country to contribute more than 10% of our total revenues, comprising 52% of revenues in 2005, 56% of revenues in 2004 and 60% of revenues in 2003. Japan is our second-largest national market, with 7% of our revenues in
2005 and 6% in each of 2004 and 2003.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">For a geographic breakdown of revenues and changes in revenues, see the table captioned </FONT><I><FONT size=2 face="serif">Geographic </FONT></I><FONT size=2 face="serif">in Note 19 to our
consolidated financial statements, </FONT><I><FONT size=2 face="serif">Segment, Geographic and Revenue Information, </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report and the table captioned </FONT><I><FONT size=2 face="serif">Change
in Geographic Revenues </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report. Those tables are incorporated by reference.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our international businesses are subject, in varying degrees, to a number of risks inherent in carrying on business in other countries. These include currency fluctuations, capital and exchange
control regulations, expropriation and other restrictive government actions. Our international businesses are also subject to government-imposed constraints, including laws on pricing or reimbursement for use of products.</FONT></P>
<P align="center">
<FONT size=2 face="serif">7</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">See </FONT><I><FONT size=2 face="serif">Government Regulation and Price Constraints </FONT></I><FONT size=2 face="serif">below for discussion of these matters.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Depending on the direction of change relative to the U.S. dollar, foreign currency values can increase or decrease the reported dollar value of our net assets and results of operations. In
2005, revenues were favorably impacted by foreign exchange, as foreign currency movements relative to the U.S. dollar increased our reported revenues in many countries. While we cannot predict with certainty future changes in foreign exchange rates
or the effect they will have on us, we attempt to mitigate their impact through operational means and by using various financial instruments. See the discussion under Note 9-D to our consolidated financial statements, </FONT><I><FONT size=2
face="serif">Financial Instruments: Derivative Financial Instruments and Hedging Activities </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report. That discussion is incorporated by reference. Related information about valuation and
risks associated with such financial instruments in parts E and F of that same Note is also incorporated by reference.</FONT></P>
<P>
<B><FONT face="serif">Marketing</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In our global Human Health business, we promote our products to healthcare providers and patients. Through our marketing organizations, we explain the approved uses, benefits and risks of our
products to healthcare providers, such as doctors, nurse practitioners, physician assistants, pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. We also market directly to consumers
in the U.S., through direct-to-consumer print and television advertising that communicates the approved uses, benefits, and risks of our products while continuing to motivate people to have meaningful conversations with their doctors. In addition,
we sponsor general advertising to educate the public on disease awareness, important public health issues, and our patient assistance programs in all major markets.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our operations include several pharmaceutical sales organizations. Our structure aligns the sales, marketing, and medical functions to work closely in tandem along the same therapeutic groups
of products, reinforcing common coordination, focus, and accountability across the organizations.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly
to retailers, hospitals, clinics, government agencies and pharmacies. We seek
to gain access to health authority, PBM and MCO formularies (lists of recommended,
approved, and/or reimbursed medicines and other products) by demonstrating the
clinical and economic value of our products. We also work with MCOs and PBMs
and other appropriate healthcare providers to assist them with disease management,
patient education and other tools that help their medical treatment routines.
In 2005, for instance, we were awarded a Center for Medicare/Medicaid Studies
(&#147;CMS&#148;) contract to provide the Green Ribbon Health Initiative, a joint-partnership
with the MCO Humana designed to improve the health and quality of life for beneficiaries
with multiple chronic conditions in Central Florida.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Consumer Healthcare business primarily uses its own representatives to directly promote its products, including marketing certain products directly to professionals using a professional
detail force. We also use print and television consumer advertising and offer sales incentives such as coupons. Our consumer healthcare products are sold through various channels.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Animal Health business also uses its own sales organization to promote its products. Its advertising and promotion are generally targeted to health professionals, directly and through
veterinary journals. Animal health and nutrition products are sold through veterinarians, drug wholesalers, distributors and retail outlets as well as directly to users. Where appropriate, these products are also marketed through print and
television advertising.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">During 2005, sales to our three largest customers were as follows:</FONT></P>
<UL>
<LI>
<FONT size=2 face="serif">McKesson, Inc. &#151; 18% of our total revenues;</FONT></LI>
<LI>
<FONT size=2 face="serif">Cardinal Health, Inc. &#151; 13% of our total</FONT> <FONT size=2 face="serif">revenues; and</FONT></LI>
<LI>
<FONT size=2 face="serif">AmerisourceBergen Corporation &#151; 10% of</FONT> <FONT size=2 face="serif">our total revenues.</FONT></LI>
</UL>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Sales to these wholesalers were concentrated in the Human Health segment. Apart from these instances, none of our business segments is dependent on any one customer or group of related
customers.</FONT></P>
<P align="center">
<FONT size=2 face="serif">8</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<B><FONT face="serif">Patents and Intellectual Property Rights</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our products are sold around the world under brand-name, logo and certain product design trademarks that we consider in the aggregate to be of material importance. Trademark protection
continues in some countries for as long as the mark is used and, in other countries, for as long as it is registered. Registrations generally are for fixed, but renewable, terms.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We own or license a number of U.S. and foreign patents. These patents cover pharmaceutical and other products and their uses, pharmaceutical formulations, product manufacturing processes and
intermediate chemical compounds used in manufacturing.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is
obtained. The actual protection afforded by a patent, which can vary from country to country, depends upon the type of patent, the scope of its coverage and the availability of legal remedies in the country.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In the aggregate, our patent and related rights are of material importance to our businesses in the U.S. and most other countries. Based on current product sales, and considering the vigorous
competition with products sold by others, the patent rights we consider significant in relation to our business as a whole, together with the year in which the U.S. basic product patent expires (including, where applicable, the additional six-month
pediatric exclusivity period), are those for the drugs set forth in the table below. The table also includes patent expiration information relating to certain recently approved drugs.</FONT></P>
<hr size="1" noshade>
<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=center>
<B><FONT size=2 face="serif">U.S. Basic Product Patent</FONT></B>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<B><U><FONT size=2 face="serif">Drug</FONT></U></B>&nbsp;
	</TD>
	<TD align=center>
<B><U><FONT size=2 face="serif">Expiration Year</FONT></U></B>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Zoloft</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2006</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Norvasc</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2007</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Zyrtec</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2007</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Camptosar</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2008</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Aricept</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2010</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Lipitor</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2010</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Xalatan</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2011</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Viagra</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2012</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Detrol</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2012</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Celebrex</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2013</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Lyrica</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2013</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=center>
<I><FONT size=2 face="serif">Sutent</FONT></I>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">2021</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=2>
<HR noshade size=1>
	</TD>
</TR>
</TABLE>
<BR>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In some instances, there are later-expiring patents relating to our products directed to particular forms or compositions of the drug or to methods of manufacturing or using the drug in the
treatment of particular diseases or conditions. However, in some cases, such patents may not protect the Company&#146;s drug from generic competition after the expiration of the basic patent.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The U.S. basic product patent for </FONT><I><FONT size=2 face="serif">Zithromax </FONT></I><FONT size=2 face="serif">expired in November 2005.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">is patented by the Belgian company UCB S.A. and is licensed to us for sales in the U.S., Canada, Europe, Mexico and Australia. We co-promote
</FONT><I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2 face="serif">as a prescription medicine in the U.S. with a subsidiary of UCB S.A. and have a license to sell </FONT><I><FONT size=2 face="serif">Zyrtec </FONT></I><FONT size=2
face="serif">under various trade names as an OTC medicine in the other markets.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Aricept </FONT></I><FONT size=2 face="serif">is patented by Eisai Co., Ltd. We co-promote </FONT><I><FONT size=2 face="serif">Aricept </FONT></I><FONT size=2 face="serif">with Eisai in the
U.S. and several other countries and have an exclusive license to sell the drug in certain other countries.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In addition to our U.S. basic product patent for </FONT><I><FONT size=2 face="serif">Lipitor</FONT></I><FONT size=2 face="serif">, which (including the pediatric exclusivity period) expires in
March 2010, we have a patent covering specifically the enantiomeric form of the drug, which (including the pediatric exclusivity period) expires in June 2011.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We market </FONT><I><FONT size=2 face="serif">Genotropin </FONT></I><FONT size=2 face="serif">in the U.S. under a non-exclusive license from Novo-Nordisk.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Companies have filed applications with the FDA seeking approval of products that we believe infringe our patents covering, among other products, </FONT><I><FONT size=2 face="serif">Lipitor,
Norvasc</FONT></I><FONT size=2 face="serif">, </FONT><I><FONT size=2 face="serif">Celebrex </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Detrol.</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We also have other patent rights covering additional products that have lesser revenues.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The expiration of a basic product patent or loss of patent protection resulting from a legal challenge normally results in significant competition from generic products against the originally
patented product and can result in a significant reduction in sales of that product in a very short period. In some cases, however, we can continue to obtain commercial benefits from product manufacturing trade secrets; patents on uses for products;
patents on processes and intermediates for the economical manufacture of the active ingredients; patents for special formulations of the product or delivery mechanisms; and conversion of the active ingredient to OTC products.</FONT></P>
<P align="center">
<FONT size=2 face="serif">9</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">One of the main limitations on our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products. Under international agreements in
recent years, global protection of intellectual property rights is improving. The General Agreement on Tariffs and Trade requires participant countries to amend their intellectual property laws to provide patent protection for pharmaceutical
products by the end of a ten-year transition period. A number of countries are doing this. We have experienced significant growth in our businesses in some of those nations, and our continued business expansion in those countries depends to a large
degree on further patent protection improvement.</FONT></P>
<P>
<B><FONT face="serif">Competition</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our businesses are conducted in intensely competitive and often highly regulated markets. Many of our human pharmaceutical products face competition in the form of branded drugs or generic
drugs that treat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of use, and cost effectiveness. Though the means of competition vary among product categories and business groups, demonstrating the
value of our products is a critical factor for success in all of our principal businesses.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Human Health business is the largest in the world. Our competitors include other worldwide research-based drug companies, smaller research companies with more limited therapeutic focus, and
generic drug manufacturers. We compete with other companies that manufacture and sell products that treat similar diseases or indications as our major products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Such competition affects our core product innovation business, focused on discovering and marketing products that satisfy unmet medical needs and providing therapeutic improvements. Our
emphasis on innovation is underscored by our multi-billion-dollar investment in research and development over the past decade, resulting in one of the strongest product pipelines in the industry. We also continue to enhance the organizational
effectiveness of our pharmaceutical sales and marketing functions, coordinating support for our salespeople&#146;s efforts to launch and promote our products to our customers.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Operating conditions have become more challenging under the mounting global pressures of competition, industry regulation and cost containment. We are taking important measures to address this
business environment. We continue to evaluate, adapt, and improve our business practices to better meet customer and public needs. For instance, we have taken an industry-leading role in evolving our approaches to direct-to-consumer advertising and
medical education grants. We have also restructured our U.S. sales organization to streamline customer interactions with our field force, ensuring that each doctor will interface with no more than two sales representatives per therapeutic area.
Finally, we continue to sponsor programs to address patient affordability and access barriers, as we strive to advance fundamental health system change through campaigns for better healthcare solutions.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Consumer Healthcare business is one of the largest in the world. However, many other companies, large and small, manufacture and sell one or more products that are similar to our consumer
healthcare products, including major retail customers that sell &#147;private label&#148; or &#147;house&#148; brands. Sources of competitive advantage include product quality and efficacy, including differentiated claims, brand identity,
advertising and promotion, product innovation, broad distribution capabilities and price. Significant expenditures for advertising, promotion and marketing are generally required to achieve and maintain both consumer and trade acceptance of consumer
healthcare products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">While our Animal Health business is one of the largest in the world, many other companies offer competitive products. Altogether, there are hundreds of producers of animal health products
throughout the world. The principal methods of competition vary somewhat depending on the particular product. They include product innovation, quality, price, service and effective promotion to veterinary professionals and consumers.</FONT></P>
<P>
<I><FONT size=2 face="serif">Managed Care Organizations</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The growth of MCOs in the U.S. has been a major factor in the competitive make-up of the healthcare marketplace. Approximately 180 million people in the U.S. now participate in some version of
managed care. Because of the size of</FONT></P>
<P align="center">
<FONT size=2 face="serif">10</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">the patient population covered by MCOs, marketing of prescription drugs to them and the PBMs that serve many of those organizations has become important to our business.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">MCOs can include medical insurance companies, medical plan administrators, health-maintenance organizations, alliances of hospitals and physicians and other physician organizations. The
purchasing power of MCOs has been increasing in recent years due to their growing numbers of enrolled patients. At the same time, those organizations have been consolidating into fewer, even larger entities. This enhances their purchasing strength
and importance to us.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The growth of MCOs has increased pressure on drug prices. A major objective of MCOs is to contain and, where possible, reduce healthcare expenditures. They typically use formularies, volume
purchases and long-term contracts to negotiate discounts from pharmaceutical providers. They use their purchasing power to bargain for lower supplier prices. They also emphasize primary and preventive care, out-patient treatment and procedures
performed at doctors&#146; offices and clinics. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed. Since the use of certain drugs can prevent the need for hospitalization, professional therapy or
even surgery, such drugs can become favored first-line treatments for certain diseases.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">As discussed above in </FONT><I><FONT size=2 face="serif">Marketing</FONT></I><FONT size=2 face="serif">, MCOs and PBMs typically develop formularies to reduce their cost for medications.
Formularies can be based on the prices and therapeutic benefits of the available products. Due to their generally lower cost, generic medicines are often favored. The breadth of the products covered by formularies can vary considerably from one MCO
to another and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs use a variety of means to encourage patients&#146; use of products listed on their formularies.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Exclusion of a product from a formulary or other restrictions, such as requiring prior authorizations, can lead to its sharply reduced usage in the MCO patient population. Consequently, pharmaceutical companies compete aggressively to have their products included. </FONT><FONT size=2 face="serif">Where possible, companies compete for inclusion based upon unique features of their products, such as greater efficacy, better patient ease of use or fewer side effects. A lower overall cost of therapy is also an important
factor. Products that demonstrate fewer therapeutic advantages must compete for inclusion based primarily on price. We have been generally, although not universally, successful in having our major products included on most MCO
formularies.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The impact of MCOs on drug prices and volumes may increase as the result of their role in negotiating on behalf of Medicare beneficiaries in connection with the new Medicare out-patient
Prescription Drug Benefit, Medicare Part D, effective January 1, 2006. MCOs and PBMs negotiate on behalf of the federal government as Prescription Drug Plans or PDPs. We have been generally, although not universally, successful in having our major
products that are used by the senior population included on the formularies of the new Medicare PDPs.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Another way we demonstrate the value of pharmaceuticals in the context of an appropriate approach to the management of healthcare is by developing disease management programs. These programs
can improve patient care by improving patient communications and compliance with dosage directions. They can also help show that a comprehensive approach to healthcare management, which includes prevention, diagnosis and treatment of certain
conditions, and appropriate use of pharmaceuticals, can improve the quality of care and lower costly complications of chronic diseases. As noted above in </FONT><I><FONT size=2 face="serif">Marketing</FONT></I><FONT size=2 face="serif">, in 2005 we
were awarded a CMS contract to provide the Green Ribbon Health Initiative, a joint-partnership with the MCO Humana, designed to improve the health and quality of life for beneficiaries with multiple chronic conditions in Central Florida.
Additionally, we sponsor a program offered by the State of Florida Agency for Health Care Administration to help manage chronic diseases among Florida&#146;s Medicaid population.</FONT></P>
<P>
<I><FONT size=2 face="serif">Generic Products</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">One of the biggest competitive challenges that we face in the U.S., which is also growing internationally, is from generic pharmaceutical manufacturers. Upon the expiration or loss of</FONT></P>
<P align="center">
<FONT size=2 face="serif">11</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">patent protection for a product, we can lose the major portion of sales of that product in a very short period. Several such competitors make a regular practice of challenging our product patents before their expiry.
Generic competitors operate without our large research and development expenses and our costs of conveying medical information about the product to the medical community. In addition, the FDA approval process exempts generics from costly and
time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. Generic products, however, need only demonstrate a level of availability in the
bloodstream equivalent to that of the innovator product. This means that generic competitors can market a competing version of our product after the expiration or loss of our patent and charge much less.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In addition, our patent-protected products can face competition in the form of generic versions of branded products of competitors that lose their market exclusivity. For example,
</FONT><I><FONT size=2 face="serif">Lipitor </FONT></I><FONT size=2 face="serif">will begin to face competition from generic pravastatin (Pravachol) and generic simvastatin (Zocor) during 2006.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">As noted above, MCOs that focus primarily on the immediate cost of drugs often favor generics over brand-name drugs. Many governments also encourage the use of generics as alternatives to
brand-name drugs in their healthcare programs, including Medicaid in the U.S. Laws in the U.S. generally allow, and in some cases require, pharmacists to substitute generic drugs that have been rated under government procedures to be therapeutically
equivalent to brand-name drugs. The substitution must be made unless the prescribing physician expressly forbids it. In the U.S., Pfizer&#146;s Greenstone subsidiary sells generic versions of Pfizer&#146;s pharmaceutical products upon loss of
exclusivity, as appropriate.</FONT></P>
<P>
<B><FONT face="serif">Raw Materials</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Raw materials essential to our businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are available from multiple sources. No
serious shortages or delays were encountered in 2005, and none are expected in 2006.</FONT></P>
<P>
<B><FONT face="serif">Government Regulation and Price Constraints</FONT></B></P>
<P>
<I><FONT size=2 face="serif">In the United States</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT size=2 face="serif">General.</FONT></U><FONT size=2 face="serif"> </FONT><FONT size=2 face="serif">Pharmaceutical companies are subject to extensive regulation by national, state and local agencies in the countries in which they do business.
Of particular importance is the FDA in the U.S. It has jurisdiction over our human pharmaceutical business and administers requirements covering the testing, safety, effectiveness, manufacturing, labeling, marketing, advertising and post-marketing
surveillance of our pharmaceutical products. The FDA also regulates most of our consumer healthcare products and, along with the U.S. Department of Agriculture and the U.S. Environmental Protection Agency, our animal health products.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In addition, many of our activities are subject to the jurisdiction of various other federal regulatory and enforcement departments and agencies, such as the Department of Health and Human
Services, the Federal Trade Commission and the Department of Justice. Individual states, acting through their attorneys general, have become active as well, seeking to regulate the marketing of prescription drugs under state consumer protection and
false advertising laws.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We are subject to possible administrative and legal proceedings and actions by these various regulatory bodies (see Note 18 to our consolidated financial statements, </FONT><I><FONT size=2
face="serif">Legal Proceedings and Contingencies, </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report). Such actions may include product recalls, seizures and other civil and criminal sanctions.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The FDA is considering changes to its approach to &#147;follow-on biological&#148; products (which are the biological product equivalent to generic pharmaceutical products). Changes that would
facilitate the approval of such products could have an adverse impact on the Company&#146;s business.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT size=2 face="serif">Medicare</FONT></U><FONT size=2 face="serif">. In December 2003, the Medicare Prescription Drug Improvement and Modernization Act of 2003 (the 2003 Medicare Act) was enacted. Medicare
beneficiaries are now eligible to obtain subsidized prescription drug coverage from a private sector provider. It remains difficult to predict the impact of the 2003</FONT></P>
<P align="center">
<FONT size=2 face="serif">12</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">Medicare Act on pharmaceutical companies. Usage of pharmaceuticals may increase as the result of the expanded access to medicines afforded by the partial reimbursement under Medicare. Such potential sales increases,
however, may be offset by increased pricing pressures due to the enhanced purchasing power of the private sector providers that negotiate on behalf of Medicare beneficiaries. Effective January 1, 2007, reimbursement under Medicare for ED medicines,
including </FONT><I><FONT size=2 face="serif">Viagra</FONT></I><FONT size=2 face="serif">, will end.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pfizer is committed to helping those without coverage gain access to Pfizer products. To that end, in 2004, we implemented our Helpful Answers program, an umbrella program that includes
existing Pfizer patient assistance programs, as well as Pfizer Pfriends, a new prescription discount card offering savings on Pfizer prescription medicines to all uninsured Americans, regardless of age or income. In January 2005, we also joined
Together Rx Access with nine other pharmaceutical companies to offer savings on over 275 medicines to Medicare-ineligible, uninsured individuals under 65 who fall below certain income thresholds. Pfizer also participates in another industry program,
the Partnership for Prescription Assistance, a single point of access to more than 475 public and private patient assistance programs.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT size=2 face="serif">Importation of Drugs</FONT></U><FONT size=2 face="serif">. There is considerable political pressure to allow the importation into the U.S. of prescription drugs that are marketed outside the
U.S. and sold at prices that are regulated by the governments of various foreign countries. In addition to raising safety concerns, such importation could impact pharmaceutical prices in the U.S. While the 2003 Medicare Act maintains the current
prohibition on such imports, it would allow importation from Canada if the Secretary of Health and Human Services certifies that such importation is safe and would result in savings to consumers. Before the 2003 Medicare Act, federal law would have
permitted importation of medicines into the U.S. from a considerably larger group of developed countries, provided the Secretary of Health and Human Services made the same safety and cost-savings certifications. On December 21, 2004, the Department
of Health and Human Services (HHS) and the Department of Commerce issued their reports on drug importation and foreign price controls. The HHS report noted that it would
be &#147;extraordinarily difficult to ensure that drugs personally imported by individual consumers&#148; could meet the standards of safety that would support certifying as safe such importation. While the report
also concluded that the U.S. could establish a feasible basis for commercial drug importation, such a change in the law would require &#147;new legal authorities, substantial additional resources and significant restrictions on the types of drugs
that could be imported.&#148; The report also noted that the total savings to be expected from such a commercial importation regime would be relatively small &#151; 1%
or 2% of total drug spending in the U.S. The Commerce Department report confirmed
that the lower prices in many countries result from governmental price controls,
and these price controls adversely affect the amount of funding that is available
for the discovery of new drugs.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT size=2 face="serif">Medicaid and Related Matters</FONT></U><FONT size=2 face="serif">. Federal law requires us to give rebates to state Medicaid agencies based on each state&#146;s reimbursement of
pharmaceutical products under the Medicaid program. In recent years, various proposals have been offered at the federal and state levels that would bring about major changes in the Medicaid program. A national commission is currently studying
changes to the Medicaid program. In the short term, driven by budget concerns, many states have implemented restrictive drug lists and state supplemental rebate programs under the Medicaid program. These programs require deeper rebate payments by
Pfizer in order to have our products listed on formularies in states with such rebate programs. More than 35 states have implemented some form of formulary restrictions in their Medicaid programs. Currently, Pfizer enjoys relatively good formulary
access in state Medicaid programs.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Effective January 1, 2006, federal funds may not be used for reimbursement of erectile dysfunction medications by the Medicaid program. In addition, effective January 1, 2007, changes to
treatment of authorized generics for purposes of calculating Medicaid rebates will increase the amount of rebates we are required to pay on brand name drug sales after loss of exclusivity and on authorized generic sales to the Medicaid
program.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">If changes are implemented under the Medicaid program that further restrict the access of a significant number of patients to our products</FONT></P>
<P align="center">
<FONT size=2 face="serif">13</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">and require significantly deeper rebate payments, our business could be adversely affected. The impact of any such changes on Pfizer would be mitigated by the shrinking size of the Medicaid market. Those people who are
eligible for both Medicaid and Medicare (often called &#147;dual eligibles&#148;) had been receiving their drug benefits under the Medicaid program. Beginning in 2006, their coverage is being transferred to the new Medicare Part D program. This will
reduce the number of enrollees in Medicaid drug programs by about 14% but reduce the amount of spending on pharmaceuticals under Medicaid by approximately 57%. While the Medicaid market is now smaller, changes at the state level could impact larger
federal and commercial accounts.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In addition, some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid eligible, as well as various approaches to
controlling pharmaceutical marketing. A sweeping price control ballot proposal was defeated in California during 2005.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We also must give discounts or rebates on purchases or reimbursements of pharmaceutical products by certain other federal and state agencies and programs. See the discussion regarding rebates
in the Revenues section of our 2005 Financial Report and in Note 1-G to our consolidated financial statements, </FONT><I><FONT size=2 face="serif">Significant Accounting Policies, Revenues, </FONT></I><FONT size=2 face="serif">in our 2005 Financial
Report, which discussions are incorporated by reference.</FONT></P>
<P>
<I><FONT size=2 face="serif">Outside the United States</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We encounter similar regulatory and legislative issues in most other countries. In Europe and some other international markets, the government provides healthcare at low direct cost to
consumers and regulates pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system. This international patchwork of price regulation has led to different prices and some third-party trade in
our products from markets with lower prices. Such trade exploiting price differences between countries can undermine our sales in markets with higher prices.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The approval of new drugs across the E.U. may only be achieved using the Mutual Recognition
Procedure/Decentralized Procedure or E.U. Commission/EMEA&#146;s Central Approval
Process, which applies in the 25 E.U. member states (ten new member states joined
the E.U. in May 2004, which has extended the scope of these procedures), plus
Norway and Iceland which are full participants in these registration processes.
The use of these procedures provides a more rapid and consistent approval across
the member states than was the case when the approval processes were operating
independently within each country.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Since the E.U. does not have jurisdiction over patient reimbursement or pricing matters in its member states, we continue to deal with individual countries on such matters across the
region.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">During 2004, a comprehensive package of reforms was adopted (called New Medicines Legislation) amending E.U. law on the regulation of medicinal products in many areas, including approval
procedures and safety reporting. Of particular note, the data exclusivity periods during which innovative companies&#146; regulatory data are protected are required to be harmonized in all member states and implementation is underway in most member
states, which will facilitate the approval and launch of generic medicines. In addition, these reforms introduced a clear legal basis for the approval of &#147;biosimilar&#148; or &#147;follow-on biological&#148; products in the E.U. Following a
positive scientific assessment announced in January 2006, we expect that the first such product, a biosimilar version of </FONT><I><FONT size=2 face="serif">Genotropin, </FONT></I><FONT size=2 face="serif">will be approved in the E.U. this year.
This new set of regulations, which took effect in November 2005, also shortens certain approval timelines and introduces fast-track and conditional centralized authorizations.</FONT></P>
<P>
<B><FONT face="serif">Environmental Law Compliance</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Most of our operations are affected by federal, state and/or local environmental laws. We have made, and intend to continue to make, necessary expenditures for compliance with applicable laws.
We also are cleaning up environmental contamination from past industrial activity at certain sites (see Note 18 to our consolidated financial statements, </FONT><I><FONT size=2 face="serif">Legal Proceedings and Contingencies, </FONT></I><FONT
size=2 face="serif">in our 2005 Financial Report). As a result, we incurred capital and operational expenditures in 2005 for environmental</FONT></P>
<P align="center">
<FONT size=2 face="serif">14</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">compliance purposes and for the clean-up of certain past industrial activity as follows:</FONT></P>
<UL>
<LI>
<FONT size=2 face="serif">environment-related capital expenditures &#151;</FONT> <FONT size=2 face="serif">&#36;87 million</FONT></LI>
<LI>
<FONT size=2 face="serif">other environment-related expenses &#151; &#36;287</FONT> <FONT size=2 face="serif">million</FONT></LI>
</UL>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">While we cannot predict with certainty future capital expenditures or operating costs for environmental compliance, we do not believe they will have a material effect on our capital
expenditures or competitive position.</FONT></P>
<P>
<B><FONT face="serif">Tax Matters</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The discussion of tax-related matters in Note 7 to our consolidated financial statements, </FONT><I><FONT size=2 face="serif">Taxes on Income</FONT></I><FONT size=2 face="serif">, in our 2005
Financial Report, is incorporated by reference.</FONT></P>
<P>
<B><FONT face="serif">Employees</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In our innovation-intensive business, our employees are vital to our success. We believe we have good relationships with our employees. As of December 31, 2005, we employed approximately
106,000 people in our operations throughout the world.</FONT></P>
<P>
<B><FONT face="serif">ITEM 1A. RISK FACTORS AND CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The statements in this Section describe the major risks to our business and should be considered carefully. In addition, these statements constitute our cautionary statements under the Private
Securities Litigation Reform Act of 1995.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">Our disclosure and analysis in this 2005 Form 10-K and in our 2005 Annual Report to Shareholders contain some forward-looking statements that set forth anticipated results based on
management&#146;s plans and assumptions. From time to time, we also provide forward-looking statements in other materials we release to the public as well as oral forward-looking statements. Such statements give our current expectations or forecasts
of future events; they do not relate strictly to historical or current facts. We have tried, wherever possible, to identify such statements by using words such as &#147;anticipate,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;target&#148;, &#147;forecast&#148; and
similar expressions in connection with any discussion of future operating or
financial performance. In particular, these include statements relating to future
actions, prospective products or product approvals, future performance or results
of current and anticipated products, sales efforts, expenses, interest rates,
foreign exchange rates, the outcome of contingencies, such as legal proceedings,
and financial results.</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to
risks, uncertainties and potentially inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those
anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements.</FONT></I></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT size=2 face="serif">We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further
disclosures we make on related subjects in our 10-Q and 8-K reports to the SEC. Also note that we provide the following cautionary discussion of risks, uncertainties and possibly inaccurate assumptions relevant to our businesses. These are factors
that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You
should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties.</FONT></I></P>
<P>
<B><FONT face="serif">Government Regulation and Managed Care Trends</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">U.S. and foreign governmental regulations mandating price controls and limitations on patient access to our products impact our business, and our future results could be adversely affected by
changes in such regulations. In the U.S., many of</FONT></P>
<P align="center">
<FONT size=2 face="serif">15</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">our pharmaceutical products are subject to increasing pricing pressures. Such pressures may increase as the result of the 2003 Medicare Act. In addition, MCOs as well as Medicaid and other government agencies continue to
seek price discounts. Government efforts to reduce Medicaid expenses may continue to increase the use of MCOs. This may result in managed care&#146;s influencing prescription decisions for a larger segment of the population and a corresponding
constraint on prices for our products. In addition, some states have implemented and other states are considering price controls or patient-access constraints under the Medicaid program and some states are considering price-control regimes that
would apply to broader segments of their populations that are not Medicaid eligible. Other matters also could be the subject of U.S. federal or state legislative or regulatory action that could adversely affect our business, including the
importation of prescription drugs that are marketed outside the U.S. and sold at prices that are regulated by the governments of various foreign countries</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The prohibition on the use of federal funds for reimbursement of ED medications by the Medicaid program, which became effective January 1, 2006, and the similar federal funding prohibition for
the Medicare program which is scheduled to take effect January 1, 2007, may adversely affect our business. Any prohibitions on the use of federal funds for reimbursement of other classes of drugs in the future may also have an adverse
effect.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We encounter similar regulatory and legislative issues in most other countries. In Europe and some other international markets, the government provides healthcare at low direct cost to
consumers and regulates pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system. This international patchwork of price regulation has led to different prices and some third-party trade in
our products from markets with lower prices. Such trade exploiting price differences between countries can undermine our sales in markets with higher prices. As a result, it is expected that pressures on the pricing component of operating results
will continue.</FONT></P>
<P>
<B><FONT face="serif">Generic Competition</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Competition from manufacturers of generic drugs is a major challenge for us in the U.S. and is growing internationally. Upon the expiration or loss of patent protection for one of our products,
or upon the &#147;at-risk&#148; launch (despite pending patent infringement litigation against the generic product) by a generic manufacturer of a generic version of one of our products, we can lose the major portion of sales of that product in a
very short period, which can adversely affect our business. The U.S. basic patent for <I>Zithromax </I>expired in 2005, and the U.S. basic patent for <I>Zoloft </I>will expire in 2006 and for each of <I>Norvasc </I>and <I>Zyrtec </I>will expire in 2007. Also, the patents covering several of our most important medicines, including <I>Lipitor</I>, <I>Norvasc</I>, <I>Celebrex </I>and <I>Detrol</I>, are
being challenged by generic manufacturers. In addition, our patent-protected products can face competition in the form of generic versions of branded products of competitors that lose their market exclusivity. For example, <I>Lipitor </I>will begin to face competition from generic pravastatin (Pravachol) and generic simvastatin (Zocor) during 2006.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Changes by the FDA to its approach to &#147;follow-on biologics&#148; could subject </FONT><I><FONT size=2 face="serif">Genotropin </FONT></I><FONT size=2 face="serif">to generic
competition.</FONT></P>
<P>
<B><FONT face="serif">Competitive Products</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We cannot predict with accuracy the timing or impact of the introduction of competitive products or their possible effect on our sales. Products that compete with our drugs, including some of
our best-selling medicines, are launched from time to time. Launches of a number of competitive products have occurred recently, and certain potentially competitive products are in various stages of development, some of which have been filed for
approval with the FDA and with regulatory authorities in other countries.</FONT></P>
<P>
<B><FONT face="serif">Dependence on Key In-Line and New Products</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We recorded product sales of more than &#36;1 billion for each of eight pharmaceutical products in 2005: <I>Lipitor, Norvasc, Zoloft, Celebrex, Zithromax/Zmax,
Viagra, Zyrtec</I>, and <I>Xalatan</I>/<I>Xalacom. </I>Those products accounted for 55% of our total 2005 revenues. <I>Lipitor </I>sales in</FONT></P>
<P align="center">
<FONT size=2 face="serif">16</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">2005 exceeded &#36;12 billion, accounting for 24% of our total 2005 revenues. If these or any of our other major products were to become subject to a problem such as loss of patent protection, changes in prescription growth
rates, material product liability litigation, unexpected side effects, regulatory proceedings, publicity affecting doctor or patient confidence or pressure from existing competitive products, or if a new, more effective treatment should be
introduced, the adverse impact on our revenues could be significant. As noted, patents covering several of our best-selling medicines recently have expired or will expire this year or next year, and patents covering a number of our best-selling
medicines are the subject of pending legal challenges. In addition, our revenues could be significantly impacted by the timing and rate of commercial acceptance of key new products, including </FONT><I><FONT size=2 face="serif">Lyrica, Exubera,
Sutent </FONT></I><FONT size=2 face="serif">and the product candidate </FONT><I><FONT size=2 face="serif">Champix</FONT></I><FONT size=2 face="serif">.</FONT></P>
<P>
<B><FONT face="serif">Uncertainty Relating to COX-2 Medicines</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our goal is to make </FONT><I><FONT size=2 face="serif">Celebrex </FONT></I><FONT size=2 face="serif">available to increased numbers of patients. However, our ability to increase
</FONT><I><FONT size=2 face="serif">Celebrex </FONT></I><FONT size=2 face="serif">sales may be limited significantly by the uncertainty concerning COX-2 medicines related to the regulatory actions involving those medicines that were taken last
year.</FONT></P>
<P>
<B><FONT face="serif">Research and Development Investment</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The discovery and development of new products as well as the development of additional uses for existing products is very important to the success of the Company. However, balancing current
growth and investment for the future remains a major challenge. Our ongoing investments in new product introductions and in research and development for new products and existing product extensions could exceed corresponding sales growth. This could
produce higher costs without a proportional increase in revenues.</FONT></P>
<P>
<B><FONT face="serif">Development, Regulatory Approval and Marketing of Products</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Risks and uncertainties particularly apply with respect to product-related, forward-looking statements. The outcome of the lengthy and complex process of identifying new compounds and developing new products is inherently uncertain. There can be no assurance as to whether or when we will receive regulatory approval for new products or for new indications
or dosage forms for existing products. Decisions by regulatory authorities regarding labeling and other matters could adversely affect the availability or commercial potential of our products. There also are many considerations that can affect
marketing of pharmaceutical products around the world. Regulatory delays, the inability to successfully complete clinical trials, claims and concerns about safety and efficacy, new discoveries, patent disputes and claims about adverse side effects
are a few of the factors that could adversely affect the realization of research and development and product-related, forward-looking statements.</FONT></P>
<P>
<B><FONT face="serif">Research Studies</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Decisions about research studies made early in the development process of a drug candidate can have a substantial impact on the marketing strategy once the drug receives approval. More detailed
studies may demonstrate additional benefits that can help in the marketing, but they consume time and resources and can delay submitting the drug candidate for initial approval. We try to plan clinical trials prudently, but there is no guarantee
that a proper balance of speed and testing will be made in each case. The quality of our decisions in this area could affect our future results.</FONT></P>
<P>
<B><FONT face="serif">Interest Rate and Foreign Exchange Risk</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">48% of our 2005 revenues were derived from international operations, including 18% from countries in the euro zone and 7% from Japan. These international-based revenues as well as our
substantial international assets expose our revenues and earnings to foreign currency exchange rate changes. In addition, our interest-bearing investments, loans and borrowings are subject to risk from changes in interest rates. These risks and the
measures we have taken to help contain them are discussed in the section entitled Financial Risk Management in our 2005 Financial Report. For additional details, see Note 9-D to our consolidated financial statements, <I>Financial Instruments: Derivative Financial Instruments and Hedging Activities</I>, in our 2005</FONT></P>
<P align="center">
<FONT size=2 face="serif">17</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">Financial Report. Those sections of our 2005 Financial Report are incorporated by reference.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Notwithstanding our efforts to foresee and mitigate the effects of changes in fiscal circumstances, we cannot predict with certainty changes in currency and interest rates, inflation or other
related factors affecting our businesses.</FONT></P>
<P>
<B><FONT face="serif">Risks Affecting International Operations</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our international operations also could be affected by changes in intellectual property legal protections and remedies, trade regulations and procedures and actions affecting approval,
production, pricing, reimbursement and marketing of products, as well as by unstable governments and legal systems and inter-governmental disputes. Any of these changes could adversely affect our business.</FONT></P>
<P>
<B><FONT face="serif">Product Manufacturing and Marketing Risks</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Difficulties or delays in product manufacturing or marketing, including, but not limited to, the inability to increase production capacity commensurate with demand, or the failure to predict
market demand for, or to gain market acceptance of, approved products, could affect future results.</FONT></P>
<P>
<B><FONT face="serif">Cost and Expense Control/Unusual Events</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Growth in costs and expenses, changes in product, segment and geographic mix and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual events that
could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, the impact of the possible sale or spin-off
of our Consumer Healthcare business and our ability to realize the projected benefits of our Adapting to Scale multi-year productivity initiative.</FONT></P>
<P>
<B><FONT face="serif">Changes in Laws and Accounting Standards</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our future results could be adversely affected by changes in laws and regulations, including changes in accounting standards, taxation requirements (including tax-rate changes, new tax laws and revised tax law interpretations), competition laws and environmental laws in the U.S. and other countries.</FONT></P>
<P>
<B><FONT face="serif">Terrorist Activity</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our future results could be adversely affected by changes in business, political and economic conditions, including the cost and availability of insurance, due to the threat of future terrorist
activity in the U.S. and other parts of the world and related U.S. military action overseas.</FONT></P>
<P>
<B><FONT face="serif">Legal Proceedings</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We and certain of our subsidiaries are involved in various patent, product liability, consumer, commercial, securities, environmental and tax litigations and claims; government investigations;
and other legal proceedings that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in
the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Patent claims include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have substantial defenses to these challenges with
respect to all our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of
that drug and could materially affect future results of operations.</FONT></P>
<P>
<B><FONT face="serif">ITEM 1B. UNRESOLVED STAFF COMMENTS</FONT></B></P>
<P>
<FONT size=2 face="serif">Not applicable.</FONT></P>
<P>
<B><FONT face="serif">ITEM 2. PROPERTIES</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our corporate headquarters and the headquarters of our Human Health and Animal Health businesses are located at our world</FONT></P>
<P align="center">
<FONT size=2 face="serif">18</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">headquarters, which includes several owned and leased buildings in New York City.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">For our Human Health business, we own and lease space around the world for sales and marketing, administrative support and customer service functions.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Global Research and Development division is headquartered in owned facilities in New London, Connecticut. We have major pharmaceutical research and development operations in owned
facilities in Ann Arbor, Kalamazoo and Portage, Michigan; Cambridge, Massachusetts; La Jolla, California; Groton, Connecticut; St. Louis, Missouri; Sandwich, England, U.K.; Amboise, France; and Nagoya, Japan. More efficient use of our R&amp;D
facilities is a component of Pfizer&#146;s Adapting to Scale initiative.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We have veterinary medicine research and development operations in owned facilities in Henrietta and Richland Township, Michigan; Lincoln, Nebraska; and Sandwich, England, U.K., and in leased
facilities in Melbourne, Australia.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The headquarters and the research and U.S. operations of our Consumer Healthcare business are located in Morris Plains, New Jersey, where we own five buildings and lease a smaller amount of
space nearby. Consumer Healthcare&#146;s sales and marketing offices in the U.S. are located in leased facilities. In most markets outside of the U.S., Consumer Healthcare&#146;s sales and marketing operations as well as administrative support are
located in owned or leased facilities shared with our Human Health and other businesses.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our Global Manufacturing division is headquartered in New York, N.Y. and in Peapack, N.J. and operates plants in 81 locations around the world that manufacture products for our Human Health,
Consumer Healthcare and Animal Health businesses. Major facilities are located in Belgium, Brazil, China, France, Germany, Ireland, Italy, Japan, Mexico, Puerto Rico, Singapore, Sweden, the United Kingdom and the United States. The Global
Manufacturing division also operates numerous distribution facilities in major markets around the world. As part of Pfizer&#146;s Adapting to Scale productivity initiative, fifteen of the manufacturing facilities are scheduled to be closed in the
next three years as Global Manufacturing continues to optimize its plant network. Studies are underway to further consolidate the distribution network.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In general, our properties are well maintained, adequate and suitable to their purposes. Note 11 to our consolidated financial statements, </FONT><I><FONT size=2 face="serif">Property, Plant
and Equipment, </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report, which discloses amounts invested in land, buildings and equipment, is incorporated by reference. See also the discussion under Note 16 to our consolidated financial
statements, </FONT><I><FONT size=2 face="serif">Lease Commitments</FONT></I><FONT size=2 face="serif">, in our 2005 Financial Report, which also is incorporated by reference.</FONT></P>
<P>
<B><FONT face="serif">ITEM 3. LEGAL PROCEEDINGS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Certain legal proceedings in which we are involved are discussed in Note 18 to our consolidated financial statements, </FONT><I><FONT size=2 face="serif">Legal Proceedings and Contingencies,
</FONT></I><FONT size=2 face="serif">in our 2005 Financial Report, which is incorporated by reference.</FONT></P>
<P>
<B><FONT face="serif">ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Not applicable.</FONT></P>
<P align="center">
<FONT size=2 face="serif">19</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<B><FONT face="serif">EXECUTIVE OFFICERS OF THE COMPANY</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The executive officers of the Company are set forth in this table. Each holds the offices indicated until his or her successor is chosen and qualified at the regular meeting of the Board of
Directors to be held immediately following the 2006 Annual Meeting of Shareholders. Each of the executive officers is a member of the Pfizer Executive Committee.</FONT></P>
<TABLE width="100%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=27% align=left>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B><U><FONT size=2 face="serif">Name</FONT></U></B>&nbsp;
	</TD>
	<TD width=5%>&nbsp;
	</TD>
	<TD width=8% align=center>
<B><U><FONT size=2 face="serif">Age</FONT></U></B>&nbsp;
	</TD>
	<TD width=6%>&nbsp;
	</TD>
	<TD width=54% align=left>
 <div align="left"><B><FONT
size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Position</U></FONT></B>&nbsp;
    </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Karen L. Katen</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">57</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Vice Chairman; President &#150; Human Health</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Jeffrey B. Kindler</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">50</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Vice Chairman and General Counsel</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Henry A. McKinnell</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">63</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Chairman of the Board and Chief Executive Officer</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">David L. Shedlarz</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">57</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Vice Chairman</FONT>&nbsp;
	</TD>
</TR>
</TABLE><BR>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information concerning Ms. Katen, Mr. Kindler, Dr. McKinnell and Mr. Shedlarz is incorporated by reference from the discussion under the headings </FONT><I><FONT size=2 face="serif">Nominees
For Directors </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Named Executive Officers Who Are Not Directors </FONT></I><FONT size=2 face="serif">in our 2006 Proxy Statement.</FONT></P>
<P align="center">
<B><FONT face="serif">PART II</FONT></B></P>
<P>
<B><FONT face="serif">ITEM 5. MARKET FOR THE COMPANY&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The principal market for our Common Stock is the New York Stock Exchange. Our stock is also listed on the London, Euronext and Swiss Stock Exchanges and is traded on various United States
regional stock exchanges. Additional information required by this item is incorporated by reference from the table captioned </FONT><I><FONT size=2 face="serif">Quarterly Consolidated Financial Data (Unaudited) </FONT></I><FONT size=2
face="serif">in our 2005 Financial Report.</FONT></P>
<P align="center">
<FONT size=2 face="serif">20</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<FONT size=2 face="serif">This table provides certain information with respect to our purchases of shares of the Company&#146;s Common Stock during the fiscal fourth quarter of 2005:</FONT></P>
<P align="center">
<B><FONT size=2 face="serif">Issuer Purchases of Equity Securities</FONT></B><SUP><FONT size=2 face="serif">(a)</FONT></SUP></P>
<hr noshade>
<TABLE width="100%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Approximate</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Total Number of</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">Dollar Value of</FONT>&nbsp;
      </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Shares Purchased as</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">Shares that May</FONT>&nbsp;
      </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Total Number of</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Average Price</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Part of Publicly</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">Yet Be Purchased</FONT>&nbsp;
      </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Period</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Shares Purchased</FONT><SUP><FONT size=2 face="serif">(b)</FONT></SUP>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Paid per Share</FONT><SUP><FONT size=2 face="serif">(b)</FONT></SUP>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">Announced Plan</FONT><SUP><FONT size=2 face="serif">(a)</FONT></SUP>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">Under the Plan</FONT><SUP><FONT size=2 face="serif">(a)</FONT></SUP>&nbsp;
      </center></TD>
</TR>
<TR>
	<TD colspan=9>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">October 3, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">through</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">October 31, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">1,987,413</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">&#36;21.20</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">1,981,700</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">&#36;4,847,380,777</FONT>&nbsp;
      </center></TD>
</TR>
<TR>
	<TD colspan=9>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">November 1, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>

	  <center>
    </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">through</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>

	  <center>
    </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">November 30, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">9,599,067</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">&#36;21.77</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">9,585,228</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">&#36;4,638,739,412</FONT>&nbsp;
      </center></TD>
</TR>
<TR>
	<TD colspan=9>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">December 1, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>

	  <center>
    </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">through</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>

	  <center>
    </center></TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">December 31, 2005</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">6,227,826</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">&#36;21.52</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">6,134,300</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=right>
      <center>
        <FONT size=2 face="serif">&#36;4,506,758,855</FONT>&nbsp;
      </center></TD>
</TR>
<TR>
	<TD colspan=9>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Total</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">17,814,306&nbsp;&nbsp;</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">&#36;21.62</FONT>&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=center>
<FONT size=2 face="serif">17,701,228</FONT>&nbsp;&nbsp;&nbsp;
	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
</TR>
<TR>
	<TD colspan=9>
      <hr noshade>  	</TD>
</TR>
</TABLE>
<BR>
<TABLE border=0 cellspacing=0 cellpadding=0>
<TR>
	<TD nowrap valign=top>
<FONT size=1 face="serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
	<TD>
<FONT size=2 face="serif">On June 23, 2005, Pfizer announced that the Board of
Directors had authorized a &#36;5 billion share- purchase plan (the &#147;2005
Stock Purchase Plan&#148;).</FONT></TD>
</TR>
<TR><TD colspan=2>&nbsp;</TD></TR><TR>
	<TD nowrap valign=top>
<FONT size=1 face="serif">(b)</FONT></TD>
	<TD>
<FONT size=2 face="serif">In addition to purchases under the 2005 Stock Purchase
Plan, this column reflects the following transactions during the fiscal fourth
quarter of 2005: (i) the deemed surrender to Pfizer of 22,708 shares of common
stock to  pay the exercise price and to satisfy tax withholding obligations in
connection with the exercise of employee stock options, (ii) the open-market
purchase by the trustee of 68,590 shares of common stock in connection with the
reinvestment of  dividends paid on common stock held in trust for employees who
were granted performance-contingent share awards and who deferred receipt of
such awards and (iii) the surrender to Pfizer of 21,780 shares of common stock
to satisfy tax withholding  obligations in connection with the vesting of restricted
stock issued to employees.</FONT></TD>
</TR>
</TABLE>
<P>
<B><FONT face="serif">ITEM 6. SELECTED FINANCIAL DATA</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information required by this item is incorporated by reference from the </FONT><I><FONT size=2 face="serif">Financial Summary </FONT></I><FONT size=2 face="serif">in our 2005 Financial
Report.</FONT></P>
<P>
<B><FONT face="serif">ITEM 7. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information required by this item is incorporated by reference from the Financial Review section of our 2005 Financial Report.</FONT></P>
<P>
<B><FONT face="serif">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information required by this item is incorporated by reference from the discussion under the heading </FONT><I><FONT size=2 face="serif">Financial Risk Management </FONT></I><FONT size=2
face="serif">in our 2005 Financial Report.</FONT></P>
<P>
<B><FONT face="serif">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information required by this item is incorporated by reference from the </FONT><I><FONT size=2 face="serif">Report of</FONT></I></P>
<P align="center">
<FONT size=2 face="serif">21</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<I><FONT size=2 face="serif">Independent Registered Public Accounting Firm on the Consolidated Financial Statements </FONT></I><FONT size=2 face="serif">in our 2005 Financial Report and from the consolidated financial statements, related notes and
supplementary data in our 2005 Financial Report.</FONT></P>
<P>
<B><FONT face="serif">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Not applicable.</FONT></P>
<P>
<B><FONT face="serif">ITEM 9A. CONTROLS AND PROCEDURES</FONT></B></P>
<P>
<B><FONT face="serif">Disclosure Controls</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">As of the end of the period covered by this 2005 Form 10-K, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal
financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;)). Based
on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our
periodic reports filed with the SEC.</FONT></P>
<P>
<B><FONT face="serif">Internal Control over Financial Reporting</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Management&#146;s report on the Company&#146;s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), and the related
report of our independent public accounting firm, are included in our 2005 Financial Report under the headings </FONT><I><FONT size=2 face="serif">Management&#146;s Report on Internal Control Over Financial Reporting </FONT></I><FONT size=2
face="serif">and </FONT><I><FONT size=2 face="serif">Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting</FONT></I><FONT size=2 face="serif">, respectively, and are incorporated by
reference.</FONT></P>
<P>
<B><FONT face="serif">Changes in Internal Controls</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">During our most recent fiscal quarter, there has not occurred any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>
<P>
<B><FONT face="serif">ITEM 9B. OTHER INFORMATION</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Not applicable.</FONT></P>
<P align="center">
<B><FONT face="serif">PART III</FONT></B></P>
<P>
<B><FONT face="serif">ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information about our Directors is incorporated by reference from the discussion under Item 1 of our 2006 Proxy Statement. Information about compliance with Section 16(a) of the Exchange Act is
incorporated by reference from the discussion under the heading <I>Section16(a) Beneficial Ownership Reporting Compliance </I>in our 2006 Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit
Committee financial experts, is incorporated by reference from the discussion under the headings </FONT><I><FONT size=2 face="serif">The Audit Committee </FONT></I><FONT size=2 face="serif">and <I>Audit Committee Financial Experts </I>in our 2006 Proxy Statement. Information about the
Pfizer Policies on Business Conduct governing our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business Conduct and Ethics governing our Directors, is incorporated by
reference from the discussion under the heading <I>Pfizer Policies on Business Ethics and Conduct </I>in our 2006 Proxy Statement. The balance of the information required by this item
is contained in the discussion entitled </FONT><I><FONT size=2 face="serif">Executive Officers of the Company </FONT></I><FONT size=2 face="serif">in Part I of this 2005 Form 10-K.</FONT></P>
<P align="center">
<FONT size=2 face="serif">22</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P>
<B><FONT face="serif">ITEM 11. EXECUTIVE COMPENSATION</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information about Director and executive compensation is incorporated by reference from the discussion under the headings </FONT><I><FONT size=2 face="serif">2005 Compensation of Non-Employee
Directors, Compensation Committee Report and Executive Compensation, Pfizer Inc. Retirement Annuity Plan, Pension Plan Table, </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Employment Agreement for Chief Executive
Officer </FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Severance Agreements </FONT></I><FONT size=2 face="serif">in our 2006 Proxy Statement.</FONT></P>
<P>
<B><FONT face="serif">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information required by this item is incorporated by reference from the discussion under the headings </FONT><I><FONT size=2 face="serif">Securities Ownership of Officers and Directors
</FONT></I><FONT size=2 face="serif">and </FONT><I><FONT size=2 face="serif">Equity Compensation Plan Information </FONT></I><FONT size=2 face="serif">in our 2006 Proxy Statement.</FONT></P>
<P>
<B><FONT face="serif">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information about certain relationships and transactions with related parties is incorporated by reference from the discussion under the heading <I>Related Party Transactions </I>in our 2006 Proxy Statement.</FONT></P>
<P>
<B><FONT face="serif">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Information about the fees for professional services rendered by our independent auditors in 2005 and 2004 is incorporated by reference from the discussion under the heading </FONT><I><FONT
size=2 face="serif">Audit and Non-Audit Fees </FONT></I><FONT size=2 face="serif">in Item 2 of our 2006 Proxy Statement. Our Audit Committee&#146;s policy on pre-approval of audit and permissible non-audit services of our independent auditors is
incorporated by reference from the section captioned </FONT><I><FONT size=2 face="serif">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm </FONT></I><FONT size=2
face="serif">in Item 2 of our 2006 Proxy Statement.</FONT></P>
<P align="center">
<FONT size=2 face="serif">23</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P align="center">
<B><FONT size=2 face="serif">PART IV</FONT></B></P>
<P>
<B><FONT size=2 face="serif">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT size=2 face="serif">15(a)(1) Financial Statements. </FONT></B><FONT size=2 face="serif">The following consolidated financial statements, related notes, report of independent registered public accounting firm and supplementary data
from our 2005 Financial Report are incorporated by reference into Item 8 of Part II of this 2005 Form 10-K:</FONT></P>
<UL>
<LI>
<FONT size=2 face="serif">Report of Independent Registered Public Accounting Firm on the Consolidated Financial</FONT> <FONT size=2 face="serif">Statements<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Consolidated Statements of Income<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Consolidated Balance Sheets<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Consolidated Statements of Shareholders&#146; Equity<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Consolidated Statements of Cash Flows<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Notes to Consolidated Financial Statements<br>
<br>
</FONT></LI>
<LI>
<FONT size=2 face="serif">Quarterly Consolidated Financial Data (Unaudited)</FONT></LI>
</UL>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT size=2 face="serif">15(a)(2) Financial Statement Schedules. </FONT></B><FONT size=2 face="serif">Schedules are omitted because they are not required or because the information is provided elsewhere in the
financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT size=2 face="serif">15(a)(3) Exhibits. </FONT></B><FONT size=2 face="serif">These exhibits are available upon request. Requests should be directed to Margaret M. Foran, Senior Vice President-Corporate
Governance, Associate General Counsel and Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, NY 10017-5755. The exhibit numbers preceded by an asterisk (*) indicate exhibits physically filed with this 2005 Form 10-K. All other exhibit
numbers indicate exhibits filed by incorporation by reference. Exhibit numbers 10(1) through 10(24) are management contracts or compensatory plans or arrangements.</FONT></P>
<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=6% align=left>
<FONT size=2 face="serif">2</FONT>&nbsp;
	</TD>
	<TD width=94% align=left>
<FONT size=2 face="serif">Agreement and Plan of Merger dated as of July 13, 2002 among Pfizer Inc., Pilsner Acquisition</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Sub Corp. and Pharmacia Corporation is incorporated by reference from Amendment No. 2 to our</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Registration Statement on Form S-4 as filed with the SEC on October 17, 2002.</FONT><SUP><FONT size=2 face="serif">1</FONT></SUP>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">3(1)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Our Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">our 10-Q report for the period ended March 28, 2004.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">3(2)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Our By-laws as amended February 24, 2005, are incorporated by reference from our 2004 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">4(1)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">incorporated by reference from our 8-K report filed on January 30, 2001.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">4(2)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Except as set forth in Exhibit 4(1) above, the instruments defining the rights of holders of long-</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">term debt securities of the Company and its subsidiaries have been omitted.</FONT><SUP><FONT size=2 face="serif">2</FONT></SUP>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left nowrap>
<FONT size=2 face="serif">10(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Annual Meeting of Shareholders.</FONT>&nbsp;
	</TD>
</TR>
</TABLE>
<BR>
<hr align="left" noshade width="200" size="1">

<P><SUP><FONT size=2 face="serif">1 </FONT></SUP><FONT size=2 face="serif">We agree to furnish to the SEC, upon request, a copy of each exhibit to this Agreement and Plan of Merger.</FONT></P>
<P>
<SUP><FONT size=2 face="serif">2 </FONT></SUP><FONT size=2 face="serif">We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.</FONT></P>
<P align="center">
<FONT size=2 face="serif">24</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=7% align=left>
<FONT size=2 face="serif">10(2)</FONT>&nbsp;
	</TD>
	<TD width=93% align=left>
<FONT size=2 face="serif">Pfizer Inc. 2004 Stock Plan is incorporated by reference from our Proxy Statement for the 2004</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Annual Meeting of Shareholders.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(3)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Form of Stock Option Grant Notice and Summary of Key Terms is incorporated by reference from</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">our 10-Q report for the period ended September 26, 2004.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(4)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Form of Restricted Stock Grant Notice is incorporated by reference from our 10-Q report for the</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">period ended September 26, 2004.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(5)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Form of Performance-Contingent Share Award Grant Notice is incorporated by reference from our</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">10-Q report for the period ended September 26, 2004.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(6)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Stock and Incentive Plan, as amended through July 1, 1999, is incorporated by reference from our</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">1999 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(7)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Pfizer Retirement Annuity Plan, as amended through November 6, 1997, is incorporated by</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">reference from our 1997 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(8)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Nonfunded Supplemental Retirement Plan is incorporated by reference from our 1996 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(9)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Nonfunded Deferred Compensation and Supplemental Savings Plan, as amended and restated as of</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">February 1, 2002, is incorporated by reference from our 2002 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(10)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Executive Annual Incentive Plan is incorporated by reference from our Proxy Statement for the</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">1997 Annual Meeting of Shareholders.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(11)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Summary of Annual Incentive Plan is incorporated by reference from our 2000 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(12)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">2001 Performance-Contingent Share Award Plan is incorporated by reference from our Proxy</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Statement for the 2001 Annual Meeting of Shareholders.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(13)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Performance-Contingent Share Award Program is incorporated by reference from our 10-Q report</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">for the period ended September 29, 1996.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(14)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Deferred Compensation Plan is incorporated by reference from our 1997 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(15)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Non-Employee Directors&#146; Retirement Plan (frozen as of October 1996) is incorporated by reference</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">from our 1996 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(16)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) is</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">incorporated by reference from our 10-Q report for the period ended September 29, 1996.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*10(17)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">effective March 1, 2006.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(18)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Restricted Stock Plan for Non-Employee Directors is incorporated by reference from our 1996 10-</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(19)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">The form of change-of-control/severance agreement with each of the Named Executive Officers</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">identified in our 2006 Proxy Statement is incorporated
by reference from our 1994 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*10(20)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">The form of Amendment, dated as of February 23, 2006, to change of control/severance</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">agreements with each of the Named Executive Officers identified in our 2006 Proxy Statement.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(21)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">The form of Indemnification Agreement with each of our non-employee Directors is incorporated</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">by reference from our 1996 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">10(22)</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">The form of Indemnification Agreement with each of the Named Executive Officers identified in</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">our 2006 Proxy Statement is incorporated by reference
from our 1997 10-K report.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left nowrap>
<FONT size=2 face="serif">10(23)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Post-Retirement Consulting Agreement, dated as of April 20, 2000, between us and William C.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Steere, Jr., is incorporated by reference from our 10-Q report for the period ended April 2, 2000.</FONT>&nbsp;
	</TD>
</TR>
</TABLE>
<BR>
<P align="center">
<FONT size=2 face="serif">25</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=7% align=left nowrap>
<FONT size=2 face="serif">10(24)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	</TD>
	<TD width=93% align=left>
<FONT size=2 face="serif">Employment Agreement, dated as of January 1, 2001, between us and Henry A. McKinnell is</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">incorporated by reference from our 8-K report filed on February 2, 2001.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*12</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Computation of Ratio of Earnings to Fixed Charges.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*13</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Portions of the 2005 Financial Report, which, except for those sections incorporated by reference,</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">are furnished solely for the information of the SEC and are not to be deemed &#147;filed.&#148;</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*21</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Subsidiaries of the Company.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*23</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Consent of KPMG LLP, Independent Registered Public Accounting Firm. </FONT></TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*24</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Power of Attorney (included as part of signature page).</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*31.1</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">2002.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*31.2</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">2002.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*32.1</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD align=left>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">*32.2</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT>&nbsp;
	</TD>
</TR>
</TABLE>
<BR>
<P align="center">
<FONT size=2 face="serif">26</FONT></P>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<P align="center">
<B><FONT face="serif">SIGNATURES</FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.</FONT></P>
<TABLE width="100%" border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=76% align=left>&nbsp;

	</TD>
	<TD width=3% colspan="2">
<FONT size=2 face="serif">Pfizer Inc.</FONT>&nbsp;
	</TD>
  </TR>
<TR valign="bottom">
  <TD align=left>&nbsp;</TD>
  <TD colspan="2">&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Dated: February 28, 2006</FONT>&nbsp;
      </div></TD>
	<TD width=3% nowrap><FONT size=2 face="serif">By:</FONT>
	&nbsp;&nbsp;</TD>
	<TD width=21% align=left>
<FONT size=2 face="serif"> /s/ Margaret M. Foran</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD>
	</TD>
	<TD>
	</TD>
	<TD>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
  <FONT size=2 face="serif">Margaret M. Foran,</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
  <FONT size=2 face="serif">Senior Vice President-Corporate</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left nowrap>
  <FONT size=2 face="serif">Governance, Associate General Counsel</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD>&nbsp;
	</TD>
	<TD align=left>
  <FONT size=2 face="serif">and Corporate Secretary</FONT>&nbsp;
	</TD>
</TR>
</TABLE>
<BR>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Margaret M. Foran and Jeffrey B. Kindler, and each of them singly, our true and lawful attorneys with full
power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.</FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date
indicated.</FONT></P>
<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=35% align=left>
<B><U><FONT size=2 face="serif">Signature</FONT></U></B>&nbsp;
	</TD>
	<TD width=40% align=left>
<B><U><FONT size=2 face="serif">Title</FONT></U></B>&nbsp;
	</TD>
	<TD width=25% align=left>
<B><U><FONT size=2 face="serif">Date</FONT></U></B>&nbsp;
	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Henry A. McKinnell</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Chairman of the Board and</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Henry A. McKinnell</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Chief Executive Officer and Director</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">(Principal Executive Officer)</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Alan G. Levin</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Senior Vice President and</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Alan G. Levin</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Chief Financial Officer</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR valign="bottom">
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>
<FONT size=2 face="serif">(Principal Financial Officer)</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Loretta V. Cangialosi</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Vice President - Controller</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Loretta V. Cangialosi</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">(Principal Accounting Officer)</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Michael S. Brown</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Michael S. Brown</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ M. Anthony Burns</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp;
	</TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">M. Anthony Burns</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Robert N. Burt</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Robert N. Burt</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ W. Don Cornwell</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">W. Don Cornwell</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ William H. Gray III</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">William H. Gray III</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Constance J. Horner</FONT></U>&nbsp;
	</TD>
	<TD align=left>
<FONT size=2 face="serif">Director</FONT>&nbsp;
	</TD>
	<TD align=left> <FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Constance J. Horner</FONT>&nbsp;
	</TD>
	<TD align=left>&nbsp;

	</TD>
	<TD align=left>&nbsp;

	</TD>
  </TR>
</TABLE>
<BR>

<HR noshade  width="100%" size=4>

<P align="left" style="page-break-before:always"></P><PAGE>


<TABLE width="100%" border=0 cellpadding=0 cellspacing=0>
<TR valign="bottom">
	<TD width=35% align=left>
<U><FONT size=2 face="serif">/s/ William R. Howell</FONT></U>&nbsp;
	</TD>
	<TD width=40% align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD width=25% align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">William R. Howell</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Stanley O. Ikenberry</FONT></U>&nbsp;
	</TD>
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Stanley O. Ikenberry</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ George A. Lorch</FONT></U>&nbsp;
	</TD>
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">George A. Lorch</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Dana G. Mead</FONT></U>&nbsp;
	</TD>
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Dana G. Mead</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ Ruth J. Simmons</FONT></U>&nbsp;
	</TD>
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">Ruth J. Simmons</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
<TR>
	<TD colspan=3>&nbsp;

	</TD>
</TR>
<TR valign="bottom">
	<TD align=left>
<U><FONT size=2 face="serif">/s/ William C. Steere, Jr.</FONT></U>&nbsp;
	</TD>
	<TD align=right>
      <div align="left"><FONT size=2 face="serif">Director</FONT>&nbsp;
      </div></TD>
	<TD align=right> <div align="left"><FONT size=2 face="serif">February 28, 2006 </FONT>&nbsp; </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left>
<FONT size=2 face="serif">William C. Steere, Jr.</FONT>&nbsp;
	</TD>
	<TD align=left>

	  <div align="left"></div></TD>
	<TD align=left>

	  <div align="left"></div></TD>
  </TR>
</TABLE>
<BR>

<HR noshade  width="100%" size=4>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
